

MYLAN LABORATORIES INC

Form 10-Q

August 07, 2007

Table of Contents

**UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549**

Form 10-Q

- QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the quarterly period ended June 30, 2007**
- OR**
- TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the transition period from to**

Commission file number 1-9114

MYLAN LABORATORIES INC.

(Exact name of registrant as specified in its charter)

Pennsylvania

(State of incorporation)

25-1211621

(I.R.S. Employer Identification No.)

1500 Corporate Drive

Canonsburg, Pennsylvania 15317

(Address of principal executive offices)

(Zip Code)

(724) 514-1800

(Registrant's telephone number, including area code)

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding twelve months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. YES NO

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer or a non-accelerated filer. See definition of "accelerated filer and large accelerated filer" in Rule 12b-2 of the Exchange Act.

Large Accelerated Filer Accelerated Filer Non-Accelerated Filer

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). YES NO

Indicate the number of shares outstanding of each of the issuer's classes of common stock, as of the latest practicable date.

Class of Common Stock	Outstanding at August 3, 2007
\$0.50 par value	248,801,646

MYLAN LABORATORIES INC. AND SUBSIDIARIES

FORM 10-Q
For the Quarterly Period Ended
June 30, 2007

INDEX

	Page Number
PART I. FINANCIAL INFORMATION	
Item 1:	Financial Statements
	<u>Condensed Consolidated Statements of Earnings Three Months Ended June 30, 2007 and 2006</u>
	3
	<u>Condensed Consolidated Balance Sheets June 30, 2007 and March 31, 2007</u>
	4
	<u>Condensed Consolidated Statements of Cash Flows Three Months Ended June 30, 2007 and 2006</u>
	5
	<u>Notes to Condensed Consolidated Financial Statements</u>
	6
<u>Item 2:</u>	Management's Discussion and Analysis of Results of Operations and Financial Condition
	25
<u>Item 3:</u>	Quantitative and Qualitative Disclosures About Market Risk
	28
<u>Item 4:</u>	Controls and Procedures
	30
<u>PART II. OTHER INFORMATION</u>	
<u>Item 1:</u>	Legal Proceedings
	30
<u>Item 1A:</u>	Risk Factors
	32
<u>Item 5:</u>	Other Information
	45
<u>Item 6:</u>	Exhibits
	46
<u>SIGNATURES</u>	47
<u>EX-10.2</u>	
<u>EX-31.1</u>	
<u>EX-31.2</u>	
<u>EX-32</u>	

Table of Contents**MYLAN LABORATORIES INC. AND SUBSIDIARIES****Condensed Consolidated Statements of Earnings**

(Unaudited; in thousands, except per share amounts)

Three Months Ended June 30,	2007	2006
Revenues:		
Net revenues	\$ 542,709	\$ 348,789
Other revenues	3,612	7,351
Total revenues	546,321	356,140
Cost of sales	249,613	167,940
Gross profit	296,708	188,200
Operating expenses:		
Research and development	31,720	21,225
Selling, general and administrative	76,914	49,826
Total operating expenses	108,634	71,051
Earnings from operations	188,074	117,149
Interest expense	22,919	10,359
Other (expense) income, net	(36,358)	9,584
Earnings before income taxes and minority interest	128,797	116,374
Provision for income taxes	49,207	40,787
Earnings before minority interest	79,590	75,587
Minority interest	(137)	
Net earnings	\$ 79,727	\$ 75,587
Earnings per common share:		
Basic	\$ 0.32	\$ 0.36
Diluted	\$ 0.32	\$ 0.35
Weighted average common shares outstanding:		
Basic	248,477	209,955
Diluted	251,604	214,791
Cash dividend declared per common share	\$ 0.06	\$ 0.06

See Notes to Condensed Consolidated Financial Statements

Table of Contents**MYLAN LABORATORIES INC. AND SUBSIDIARIES****Condensed Consolidated Balance Sheets**

(Unaudited; in thousands, except share and per share amounts)

	June 30, 2007	March 31, 2007
ASSETS		
Current assets:		
Cash and cash equivalents	\$ 1,315,557	\$ 1,252,365
Marketable securities	174,885	174,207
Accounts receivable, net	401,071	350,294
Inventories	432,348	429,111
Deferred income tax benefit	161,874	145,343
Prepaid expenses and other current assets	136,289	60,724
Total current assets	2,622,024	2,412,044
Property, plant and equipment, net	707,064	686,739
Intangible assets, net	343,808	352,780
Goodwill	610,248	612,742
Deferred income tax benefit	46,002	45,779
Other assets	146,375	143,783
Total assets	\$ 4,475,521	\$ 4,253,867

LIABILITIES AND SHAREHOLDERS EQUITY

Liabilities		
Current liabilities:		
Trade accounts payable	\$ 146,811	\$ 160,286
Short-term borrowings	107,315	108,259
Income taxes payable	91,558	78,387
Current portion of long-term obligations	130,756	124,782
Cash dividends payable	14,923	14,902
Other current liabilities	337,604	213,919
Total current liabilities	828,967	700,535
Deferred revenue	102,995	90,673
Long-term debt	1,656,064	1,654,932
Other long-term obligations	40,467	29,760
Deferred income tax liability	85,382	85,900
Total liabilities	2,713,875	2,561,800
Minority interest	36,667	43,207

Shareholders equity

Edgar Filing: MYLAN LABORATORIES INC - Form 10-Q

Preferred stock par value \$0.50 per share		
Shares authorized: 5,000,000 Shares issued: none		
Common stock par value \$0.50 per share	169,856	169,681
Shares authorized: 600,000,000 at June 30, 2007 and March 31, 2007 Shares issued: 339,712,852 at June 30, 2007 and 339,361,201 at March 31, 2007		
Additional paid-in capital	976,444	962,746
Retained earnings	2,156,667	2,103,282
Accumulated other comprehensive earnings	10,286	1,544
	3,313,253	3,237,253
Less:		
Treasury stock at cost		
Shares: 90,963,658 at June 30, 2007 and 90,948,957 at March 31, 2007	1,588,274	1,588,393
Total shareholders equity	1,724,979	1,648,860
Total liabilities and shareholders equity	\$ 4,475,521	\$ 4,253,867

See Notes to Condensed Consolidated Financial Statements

Table of Contents**MYLAN LABORATORIES INC. AND SUBSIDIARIES****Condensed Consolidated Statements of Cash Flows**

(Unaudited; in thousands)

Three Months Ended June 30,	2007	2006
Cash flows from operating activities:		
Net earnings	\$ 79,727	\$ 75,587
Adjustments to reconcile net earnings to net cash provided from operating activities:		
Depreciation and amortization	26,868	11,787
Stock-based compensation expense	4,569	6,806
Minority interest	(137)	
Net income from equity method investees	(2,281)	(5,038)
Change in estimated sales allowances	(14,090)	15,738
Deferred income tax benefit	(11,662)	(15,346)
Other non-cash items	5,932	(624)
Receipts from litigation settlements, net	1,998	2,000
Loss on foreign currency option contract	57,468	
Cash received from Somerset		5,740
Changes in operating assets and liabilities:		
Accounts receivable	(35,494)	(41,925)
Inventories	2,632	(10,747)
Trade accounts payable	(39,637)	(8,094)
Income taxes	(2,947)	49,204
Deferred revenue	12,372	(1,793)
Other operating assets and liabilities, net	(767)	9,594
Net cash provided by operating activities	84,551	92,889
Cash flows from investing activities:		
Capital expenditures	(27,869)	(27,717)
Purchase of marketable securities	(86,270)	(192,053)
Proceeds from sale of marketable securities	83,202	144,680
Other items, net	(306)	(159)
Net cash used in investing activities	(31,243)	(75,249)
Cash flows from financing activities:		
Cash dividends paid	(14,902)	(12,605)
Excess tax benefit from stock-based compensation	2,082	700
Proceeds from exercise of stock options	6,081	6,301
Change in outstanding checks in excess of cash in disbursement accounts	18,008	(7,605)
Change in short-term borrowings, net	(3,824)	
Other items, net	(1,572)	(632)
Net cash provided by (used in) financing activities	5,873	(13,841)

Edgar Filing: MYLAN LABORATORIES INC - Form 10-Q

Effect on cash of changes in exchange rates	4,011	
Net increase in cash and cash equivalents	63,192	3,799
Cash and cash equivalents beginning of period	\$ 1,252,365	\$ 150,124
Cash and cash equivalents end of period	\$ 1,315,557	\$ 153,923

See Notes to Condensed Consolidated Financial Statements

Table of Contents

MYLAN LABORATORIES INC. AND SUBSIDIARIES

**Notes to Condensed Consolidated Financial Statements
(Unaudited; in thousands, except share and per share amounts)**

1. General

In the opinion of management, the accompanying unaudited condensed consolidated financial statements (interim financial statements) of Mylan Laboratories Inc. and subsidiaries (Mylan or the Company) were prepared in accordance with accounting principles generally accepted in the United States of America and the rules and regulations of the Securities and Exchange Commission for reporting on Form 10-Q; therefore, as permitted under these rules, certain footnotes and other financial information included in audited financial statements were condensed or omitted. The interim financial statements contain all adjustments (consisting of only normal recurring adjustments) necessary to present fairly the interim results of operations, financial position and cash flows for the periods presented.

These interim financial statements should be read in conjunction with the Consolidated Financial Statements and Notes thereto in the Company s Annual Report on Form 10-K for the fiscal year ended March 31, 2007.

The interim results of operations and interim cash flows for the three months ended June 30, 2007 are not necessarily indicative of the results to be expected for the full fiscal year or any other future period.

Certain prior year amounts were reclassified to conform to the current year presentation. Such reclassifications had no impact on reported net earnings, earnings per share or shareholders equity.

2. Revenue Recognition and Accounts Receivable

Revenue is recognized for product sales upon shipment when title and risk of loss transfer to the Company s customers and when provisions for estimates, including discounts, rebates, price adjustments, returns, chargebacks and other promotional programs are reasonably determinable. No revisions were made to the methodology used in determining these provisions during the three month period ended June 30, 2007.

As a result of significant uncertainties surrounding the pricing and market conditions with respect to a product launched by the Company in late March 2007, the Company is not able to reasonably estimate the amount of potential price adjustments. Therefore, revenues on shipments of this product are currently being deferred until the resolution of such uncertainties. Such uncertainties are resolved upon our customers sale of this product. As a result, the Company is recognizing revenue at this time only upon our customers sale of this product.

Accounts receivable are presented net of allowances relating to these provisions. Such allowances were \$392,602 and \$404,687 as of June 30, 2007 and March 31, 2007, respectively. Other current liabilities include \$49,868 and \$51,873 at June 30, 2007, and March 31, 2007, for certain rebates and other adjustments that are payable to indirect customers.

3. Recent Accounting Pronouncements

In September 2006, the Financial Accounting Standards Board (FASB) issued Statement of Financial Accounting Standards (SFAS) No. 157, *Fair Value Measurements*, (SFAS No. 157), which defines fair value, establishes a framework for measuring fair value in GAAP and expands disclosures about fair value measurements. The statement is effective for fiscal years beginning after November 15, 2007. The Company is currently evaluating the impact of adopting SFAS No. 157 on its consolidated financial statements.

In February 2007, the FASB issued SFAS No. 159, *The Fair Value Option for Financial Assets and Financial Liabilities*, (SFAS No. 159), providing companies with an option to report selected financial assets and liabilities at fair value. This statement is effective for fiscal years beginning after November 15, 2007. The Company is currently evaluating the impact of adopting SFAS No. 159 on its consolidated financial statements.

Table of Contents

MYLAN LABORATORIES INC. AND SUBSIDIARIES

Notes to Condensed Consolidated Financial Statements (Continued)

4. Pending Acquisition

On May 12, 2007, Mylan and Merck KGaA announced the signing of a definitive agreement under which Mylan will acquire Merck's generics business (Merck Generics) for 4,900,000 (approximately \$6,700,000) in an all-cash transaction. Management believes that the combination of Mylan and Merck Generics will create a vertically and horizontally integrated generics and specialty pharmaceuticals leader with a diversified revenue base and a global footprint, and also believes the combined company will be among the top tier of global generic companies, with a significant presence in the top five global generics markets. The transaction remains subject to regulatory review in the United States and certain other customary closing conditions and is expected to close in the second half of calendar 2007. In connection with the pending transaction, Mylan has obtained fully committed financing from Merrill Lynch, Citigroup, Goldman Sachs, and J.P. Morgan.

In conjunction with this planned transaction, the Company entered into a deal-contingent foreign currency option contract in order to mitigate the risk of foreign currency exposure related to the pending Euro denominated transaction. The contract is contingent upon the closing of this acquisition and the premium of approximately \$121,900 will be paid only upon such closing.

The Company accounts for this instrument under the provisions of SFAS No. 133, *Accounting for Derivative Instruments and Hedging Activities* (SFAS No. 133). This instrument does not qualify for hedge accounting treatment under SFAS No. 133 and therefore is required to be adjusted to fair value with the change in the fair value of the instrument recorded in current earnings. The Company recorded a non-cash, unrealized loss of \$57,468 in the three month period ended June 30, 2007 related to this deal-contingent foreign currency option contract. This amount is included as other (expense) income, net, in the Condensed Consolidated Statement of Earnings. The fair value of this contract at June 30, 2007 is included in prepaid expenses and other current assets on the Condensed Consolidated Balance Sheet.

5. Stock-Based Incentive Plan

Mylan's shareholders approved the *Mylan Laboratories Inc. 2003 Long-Term Incentive Plan* on July 25, 2003, and approved certain amendments on July 28, 2006 (as amended, the 2003 Plan). Under the 2003 Plan, 22,500,000 shares of common stock are reserved for issuance to key employees, consultants, independent contractors and non-employee directors of Mylan through a variety of incentive awards, including: stock options, stock appreciation rights, restricted shares and units, performance awards, other stock-based awards and short-term cash awards. Awards are granted at the fair value of the shares underlying the options at the date of the grant, generally become exercisable over periods ranging from three to four years, and generally expire in ten years.

Upon approval of the 2003 Plan, the *Mylan Laboratories Inc. 1997 Incentive Stock Option Plan* (the 1997 Plan) was frozen, and no further grants of stock options will be made under that plan. However, there are stock options outstanding from the 1997 Plan, expired plans and other plans assumed through acquisitions.

Table of Contents**MYLAN LABORATORIES INC. AND SUBSIDIARIES****Notes to Condensed Consolidated Financial Statements (Continued)**

The following table summarizes stock option activity:

	Number of Shares Under Option	Weighted Average Exercise Price per Share
Outstanding at March 31, 2007	17,647,728	\$ 16.17
Options granted	101,000	19.95
Options exercised	(351,651)	14.49
Options forfeited	(124,202)	16.78
Outstanding at June 30, 2007	17,272,875	\$ 16.22
Vested and expected to vest at June 30, 2007	16,976,874	\$ 16.18
Options exercisable at June 30, 2007	11,537,656	\$ 15.04

As of June 30, 2007, options outstanding, options vested and expected to vest, and options exercisable had average remaining contractual terms of 5.97 years, 5.93 years and 5.05 years, respectively. Also at June 30, 2007, options outstanding, options vested and expected to vest and options exercisable had aggregate intrinsic values of \$44,487, \$44,352 and \$41,961, respectively.

A summary of the status of the Company's nonvested restricted stock and restricted stock unit awards as of June 30, 2007 and the changes during the three month period ended June 30, 2007, is presented below:

Restricted Stock Awards	Number of Restricted Stock Awards	Weighted Average Grant-Date Fair Value per Share
Nonvested at March 31, 2007	211,316	\$ 23.10
Granted		
Released		
Forfeited	(14,700)	23.27
Nonvested at June 30, 2007	196,616	\$ 23.09

As of June 30, 2007, the Company had \$17,466 of total unrecognized compensation expense, net of estimated forfeitures, related to all of its stock-based awards, which will be recognized over the remaining weighted average period of 1.2 years. The total intrinsic value of stock-based awards exercised during the quarter ended June 30, 2007 was \$696. The total fair value of all shares vested during the quarter ended June 30, 2007 was \$3,988.

Subsequent to June 30, 2007, the Company granted approximately 4,200,000 options and restricted stock units. Compensation expense to be recognized in future periods related to this grant will be approximately \$34,000.

Table of Contents**MYLAN LABORATORIES INC. AND SUBSIDIARIES****Notes to Condensed Consolidated Financial Statements (Continued)****6. Balance Sheet Components**

Selected balance sheet components consist of the following:

	June 30, 2007	March 31, 2007
	(In thousands)	
Inventories:		
Raw materials	\$ 153,393	\$ 148,109
Work in process	93,052	95,655
Finished goods	185,903	185,347
	\$ 432,348	\$ 429,111
Property, plant and equipment:		
Land and improvements	\$ 30,418	\$ 29,850
Buildings and improvements	337,661	297,505
Machinery and equipment	520,963	471,990
Construction in progress	88,648	141,301
	977,690	940,646
Less accumulated depreciation	270,626	253,907
	\$ 707,064	\$ 686,739
Other current liabilities:		
Payroll and employee benefit plan accruals	\$ 40,261	\$ 47,282
Accrued rebates	49,868	51,873
Royalties	11,959	15,215
Deferred revenue	20,482	17,675
Accrued interest	14,945	4,575
Legal and professional	39,750	40,095
Foreign currency option contract	121,874	
Other	38,465	37,204
Total	\$ 337,604	\$ 213,919

7. Earnings per Common Share

Basic earnings per common share is computed by dividing net earnings by the weighted average number of common shares outstanding during the period. Diluted earnings per common share is computed by dividing net earnings by the

weighted average number of common shares outstanding during the period adjusted for the dilutive effect of stock options and restricted stock outstanding. The effect of dilutive stock options on the weighted average number of common shares outstanding was 3,127,000 and 4,836,000 for the three months ended June 30, 2007 and 2006.

Stock options or restricted stock units representing 1,982,000 and 1,511,000 shares of common stock were outstanding as of June 30, 2007 and 2006, but were not included in the computation of diluted earnings per share for the three months then ended because to do so would have been anti-dilutive.

Table of Contents**MYLAN LABORATORIES INC. AND SUBSIDIARIES****Notes to Condensed Consolidated Financial Statements (Continued)****8. Goodwill and Intangible Assets**

A rollforward of goodwill from March 31, 2007 to June 30, 2007 is as follows:

	Total (In thousands)
Goodwill balance at March 31, 2007	\$ 612,742
Additions	610
Foreign currency translation and other	(3,104)
Goodwill balance at June 30, 2007	\$ 610,248

Intangible assets consist of the following components:

	Weighted Average Life (Years)	Original Cost (In thousands)	Accumulated Amortization (In thousands)	Net Book Value
June 30, 2007				
Amortized intangible assets:				
Patents and technologies	20	\$ 118,926	\$ 62,482	\$ 56,444
Product rights and licenses	8	370,052	96,491	273,561
Other	14	21,626	8,606	13,020
		\$ 510,604	\$ 167,579	343,025
Intangible assets no longer subject to amortization:				
Trademarks				783
				\$ 343,808
March 31, 2007				
Amortized intangible assets:				
Patents and technologies	20	\$ 118,927	\$ 61,000	\$ 57,927
Product rights and licenses	8	367,805	86,349	281,456
Other	14	20,821	8,207	12,614
		\$ 507,553	\$ 155,556	351,997

Intangible assets no longer subject to amortization:

Trademarks

783

\$ 352,780

Amortization expense for the three months ended June 30, 2007 and 2006 was \$11,949 and \$3,370 and is expected to be \$43,864, \$46,434, \$43,740, \$43,294, and \$37,404 for fiscal years 2008 through 2012, respectively.

Table of Contents**MYLAN LABORATORIES INC. AND SUBSIDIARIES****Notes to Condensed Consolidated Financial Statements (Continued)****9. Long-Term Debt**

A summary of long-term debt is as follows:

	June 30, 2007	March 31, 2007
	(In thousands)	
Senior Notes(A)	\$ 500,000	\$ 500,000
Credit facilities(B)	450,000	450,000
Senior convertible notes(C)	600,000	600,000
Matrix facility loans(D)	233,468	226,362
	\$ 1,783,468	\$ 1,776,362
Less: Current portion	127,404	121,430
Total long-term debt	\$ 1,656,064	\$ 1,654,932

- (A) On July 21, 2005, the Company issued \$500,000 in Senior Notes, which consisted of \$150,000 of Senior Notes due August 15, 2010, and bearing interest at 5³/₄% per annum (the 2010 Restricted Notes) and \$350,000 of Senior Notes due August 15, 2015, and bearing interest at 6³/₈% per annum (the 2015 Restricted Notes , and collectively the Restricted Notes). The Restricted Notes were exchanged on January 14, 2006, in accordance with a registration rights agreement in a transaction consummated on January 19, 2006. The form and terms of the registered notes (the Notes) are identical in all material respects to the original notes. Interest is payable semiannually on February 15 and August 15 and commenced on February 15, 2006.

Prior to maturity, the Company may, under certain circumstances, redeem the Notes in whole or in part at prices specified in the bond indenture governing the Notes. Upon a change of control (as defined in the indenture governing the Notes) of the Company, each holder of the Notes may require the Company to purchase all or a portion of such holder's Notes at 101% of the principal amount of such Notes, plus accrued and unpaid interest.

The Notes are senior unsecured obligations of the Company and rank junior to all of the Company's secured obligations. The Notes are guaranteed jointly and severally on a full and unconditional senior unsecured basis by all of the Company's wholly-owned domestic subsidiaries except a captive insurance company.

The Notes indenture contains covenants that, among other things, limit the ability of the Company to (a) incur additional secured indebtedness, (b) make investments or other restricted payments, (c) pay dividends on, redeem or repurchase the Company's capital stock, (d) engage in sale-leaseback transactions and (e) consolidate, merge or transfer all or substantially all of its assets. Certain of the covenants contained in the indenture will no longer be applicable or will be less restrictive if the Company achieves investment grade

ratings as outlined in the indenture.

- (B) On July 21, 2005, the Company entered into a \$500,000 senior secured credit facility (the Credit Facility). The Credit Facility consisted of a \$225,000 five-year revolving credit facility and a \$275,000 five-year term loan (the Term Loan).

On July 24, 2006, the Company completed the refinancing of its existing Credit Facility by entering into a credit agreement for a five-year \$700,000 senior unsecured revolving credit facility (the 2006 Credit Facility). At the Company's discretion, the 2006 Credit Facility was expandable to \$1,000,000. Borrowings totaling \$187,000 were made under the 2006 Credit Facility and, along with existing cash, were used to repay the Term Loan. Additional net borrowings of \$263,000 were made under the 2006 Credit Facility in order to finance the acquisition of Matrix. The spread over LIBOR for borrowings is adjusted based upon the Company's total leverage ratio as discussed below. The Company's obligations under the 2006 Credit Facility

Table of Contents

MYLAN LABORATORIES INC. AND SUBSIDIARIES

Notes to Condensed Consolidated Financial Statements (Continued)

are guaranteed on a senior unsecured basis by all of the Company's direct and indirect domestic subsidiaries, except a captive insurance company.

The 2006 Credit Facility includes covenants that (a) require the Company to maintain a minimum interest coverage ratio and a maximum total leverage ratio, (b) place limitations on the Company's subsidiaries' ability to incur debt, (c) place limitations on the Company's and the Company's subsidiaries' ability to grant liens, carry out mergers, consolidations and sales of all or substantially all of its assets and (d) place limitations on the Company's and the Company's subsidiaries' ability to pay dividends or make other restricted payments. The 2006 Credit Facility contains customary events of default, including nonpayment, misrepresentation, breach of covenants and bankruptcy.

On March 26, 2007, Mylan and its wholly-owned indirect subsidiary Euro Mylan B.V. (Euro Mylan) entered into a credit agreement (the Credit Agreement), effective March 26, 2007 (the Closing Date), with a syndicate of bank lenders for a \$750,000 senior unsecured credit facility including (i) a multicurrency revolving credit facility (the Revolving Credit Facility) in an aggregate amount of up to a U.S. dollar equivalent of \$300,000 due July 24, 2011, and (ii) a term loan agreement (the Term Loan Agreement) denominated in U.S. dollars to the Company in an aggregate amount of \$450,000 due December 26, 2011 (collectively, the 2007 Credit Facility).

On the Closing Date, the Company borrowed \$450,000 under the Term Loan Agreement and used the proceeds to repay the revolving loans outstanding under the Company's existing 2006 Credit Facility. The Company intends to use the Revolving Credit Facility for working capital and general corporate purposes, including expansion of its global operations.

The 2007 Credit Facility also provides that the entire principal amount of the Revolving Credit Facility may be borrowed by the Company or Euro Mylan in Euros or other foreign currencies that are agreed to by the Company and the Administrative Agent. At the request of the Company, but subject to obtaining commitments from the lenders or new lenders and the other terms and conditions specified in the Credit Agreement, the Company may elect to increase the commitments under the 2007 Credit Facility up to an aggregate amount not to exceed \$850,000. At June 30, 2007 and March 31, 2007, the Company had outstanding letters of credit of \$13,117.

At the Company's option, loans under the 2007 Credit Facility will bear interest either at a rate equal to LIBOR plus an effective applicable margin or at a base rate, which is defined as the higher of the rate announced publicly by the Administrative Agent, from time to time, as its prime rate or 0.5% above the federal funds rate. The effective applicable margin will fluctuate within a range of 0.40% to 1.00%, based on the Company's total leverage ratio. In addition, the Company is required to pay a facility fee on the average daily amount of the commitments (whether used or unused) of the Revolving Credit Facility at a rate, which ranges from 0.10% to 0.25%, based on the Company's total leverage ratio. The interest rate in effect on the outstanding borrowings under the Term Loan Agreement at June 30, 2007 and March 31, 2007 was 6.07% and 6.20%, respectively. At June 30, 2007, the Company had a total of \$1,000,000 available under the 2006 and 2007 Credit Facilities.

The Company's and Euro Mylan's obligations under the 2007 Credit Facility are guaranteed on a senior unsecured basis by all of the Company's direct and indirect domestic subsidiaries, except a captive insurance

company. Euro Mylan's obligations are also guaranteed by the Company.

The 2007 Credit Facility includes covenants similar to those of the 2006 Credit Facility. The 2007 Credit Facility contains customary events of default, including nonpayment, misrepresentation, breach of covenants and bankruptcy.

In addition, on March 26, 2007 the Company entered into an amendment (the Amendment) to the 2006 Credit Agreement to modify the interest rates to conform to the effective interest rates applicable to the Credit Agreement and to make certain other changes conforming the 2006 Credit Facility to the 2007 Credit Facility.

Table of Contents

MYLAN LABORATORIES INC. AND SUBSIDIARIES

Notes to Condensed Consolidated Financial Statements (Continued)

- (C) On March 1, 2007, Mylan entered into a purchase agreement relating to the sale by the Company of \$600,000 aggregate principal amount of the Company's 1.25% Senior Convertible Notes due 2012 (the Convertible Notes). The Convertible Notes bear interest at a rate of 1.25% per year, accruing from March 7, 2007. Interest is payable semiannually in arrears on March 15 and September 15 of each year, beginning September 15, 2007. The Convertible Notes will mature on March 15, 2012, subject to earlier repurchase or conversion. Holders may convert their notes subject to certain conversion provisions determined by, among others, the market price of the Company's common stock and the trading price of the Convertible Notes. The Convertible Notes have an initial conversion rate of 44.5931 shares of common stock per \$1,000 principal amount (equivalent to an initial conversion price of approximately \$22.43 per share), subject to adjustment, with the principal amount payable in cash and the remainder in cash or stock at the option of the Company.

On March 1, 2007, concurrently with the sale of the Convertible Notes, Mylan entered into a convertible note hedge transaction, comprised of a purchased call option, and two warrant transactions with each of Merrill Lynch International, an affiliate of Merrill Lynch, and JPMorgan Chase Bank, National Association, London Branch, an affiliate of JPMorgan, each of which we refer to as a counterparty. The net cost of the transactions was approximately \$80,600. The purchased call options will cover approximately 26,755,853 shares of our common stock, subject to anti-dilution adjustments substantially similar to the anti-dilution adjustments for the Convertible Notes, which under most circumstances represents the maximum number of shares that underlie the Convertible Notes. Concurrently with entering into the purchased call options, we entered into warrant transactions with the counterparties. Pursuant to the warrant transactions, we will sell to the counterparties warrants to purchase in the aggregate approximately 26,755,853 shares of our common stock, subject to customary anti-dilution adjustments. The warrants may not be exercised prior to the maturity of the Convertible Notes, subject to certain limited exceptions.

The purchased call options are expected to reduce the potential dilution upon conversion of the Convertible Notes in the event that the market value per share of our common stock at the time of exercise is greater than approximately \$22.43, which corresponds to the initial conversion price of the Convertible Notes. The sold warrants have an exercise price that is 60.0% higher than the price per share of \$19.50 at which we offered our common stock in a concurrent equity offering. If the market price per share of our common stock at the time of conversion of any Convertible Notes is above the strike price of the purchased call options, the purchased call options will, in most cases, entitle us to receive from the counterparties in the aggregate the same number of shares of our common stock as we would be required to issue to the holder of the converted Convertible Notes. Additionally, if the market price of our common stock at the time of exercise of the sold warrants exceeds the strike price of the sold warrants, we will owe the counterparties an aggregate of approximately 26,755,853 shares of our common stock. The purchased call options and sold warrants may be settled for cash at our election.

The purchased call options and sold warrants are separate transactions entered into by the Company with the counterparties, are not part of the terms of the Convertible Notes, and will not affect the holders' rights under the Convertible Notes. Holders of the Convertible Notes will not have any rights with respect to the purchased call options or the sold warrants. The purchased call options and sold warrants meet the definition of derivatives under SFAS No. 133 (as amended by SFAS No. 138 and SFAS No. 149). However, because these instruments have been determined to be indexed to the Company's own stock (in accordance with the guidance of Emerging Issues Task Force (EITF) Issue No. 01-6, *The Meaning of Indexed to a Company's Own Stock*) and

have been recorded in stockholders' equity in the Company's Condensed Consolidated Balance Sheet (as determined under EITF Issue No. 00-19, *Accounting for Derivative Financial Instruments Indexed to, and Potentially Settled in, a Company's Own Stock*) the instruments are exempted out of the scope of SFAS No. 133 and are not subject to the mark to market provisions of that standard.

- (D) Matrix's borrowings consist primarily of two Facilities (Facility A and Facility B) both of which are denominated in Euros. Matrix's effective interest rate for these loans is Euro Interbank Offered Rate (Euribor) plus 110 basis points for Facility A of \$82,500, or 5.19% and 4.96% at June 30, 2007 and March 31, 2007,

Table of Contents**MYLAN LABORATORIES INC. AND SUBSIDIARIES****Notes to Condensed Consolidated Financial Statements (Continued)**

respectively, and Euribor plus 129 basis points for Facility B of \$82,500, or 5.24% and 5.15% at June 30, 2007 and March 31, 2007, respectively. Facility A was due in July 2007 and Facility B is payable over three years in semi-annual installments beginning in October 2007. These loans are collateralized by the pledge of certain of Matrix subsidiaries' shares and by a Matrix corporate guarantee to ABN Amro Bank NV. These loans also require Matrix and certain of its subsidiaries to comply with certain covenants, under which the approval of the lenders is required for certain transactions which include incurring additional indebtedness or guarantees; declaration of payment of dividends; entering into acquisitions or mergers, joint ventures, consolidations or sales of Matrix assets; and entering into new lines of business. The covenants also prescribe certain maximum ratios of debt to earnings or equity ratios and minimum levels of interest and debt service coverage ratios. Subsequent to June 30, 2007, Facility A was repaid.

All financing fees associated with the Company's borrowings are being amortized over the life of the related debt. The total unamortized amounts of \$25,227 and \$26,801 are included in other assets in the Condensed Consolidated Balance Sheets at June 30, 2007 and March 31, 2007.

At June 30, 2007, and March 31, 2007, the fair value of the Convertible Notes was approximately \$581,400 and \$640,400, respectively, and the carrying values of the Notes, the Term Loan Facility, and on Matrix's term loan borrowings approximated fair value.

Certain of the Company's debt agreements contain certain cross-default provisions.

10. Comprehensive Earnings

Comprehensive earnings consists of the following:

Three Months Ended June 30, (In thousands)	2007	2006
Net earnings	\$ 79,727	\$ 75,587
Other comprehensive earnings (loss), net of tax:		
Foreign currency translation adjustments	9,934	
Change in unrecognized losses and prior service cost related to post-retirement plans	170	
Unrealized gains on securities		
Net unrealized gain on marketable securities	(1,602)	(898)
Less: Reclassification for losses included in net earnings	240 (1,362)	735 (163)
Other comprehensive earnings (loss), net of tax:	\$ 8,742	\$ (163)
Comprehensive earnings, net of tax	\$ 88,469	\$ 75,424

Accumulated other comprehensive earnings, as reflected on the balance sheet, is comprised of the following:

	June 30, 2007	March 31, 2007
	(In thousands)	
Net unrealized gain in market securities	\$ 188	\$ 1,550
Change in unrecognized losses and prior service cost related to post-retirement plans	(1,102)	(1,272)
Foreign currency translation adjustments	11,200	1,266
Accumulated other comprehensive income	\$ 10,286	\$ 1,544

Table of Contents

MYLAN LABORATORIES INC. AND SUBSIDIARIES

Notes to Condensed Consolidated Financial Statements (Continued)

11. Income Taxes

The Company adopted FASB Interpretation No. 48, *Accounting for Uncertainty in Income Taxes – an Interpretation of FASB Statement 109* (FIN 48) effective April 1, 2007. FIN 48 clarifies the accounting for uncertain tax positions. This Interpretation provides that the tax effects from an uncertain tax position be recognized in the Company's financial statements, only if the position is more likely than not of being sustained upon audit, based on the technical merits of the position. As a result of the implementation of FIN 48, the Company recognized a \$16,400 increase in its existing liability for unrecognized tax benefits, with a corresponding decrease to the April 1, 2007 retained earnings of \$11,400 and an increase to deferred tax assets of \$5,000.

As of April 1, 2007, after the implementation of FIN 48, the Company's liability for unrecognized tax benefits was \$42,900, excluding liabilities for interest and penalties. If the Company were to recognize these benefits, the effective tax rate would reflect a favorable net impact of \$33,000. In addition, at April 1, 2007, liabilities for accrued interest and penalties relating to the unrecognized tax benefits totaled \$6,300. As of June 30, 2007, the Company's Condensed Consolidated Balance Sheet reflects a liability for unrecognized tax benefits of \$43,900, excluding liabilities for interest and penalties. Accrued interest and penalties included in the Condensed Consolidated Balance Sheet were \$6,500 as of June 30, 2007.

The Company recognizes interest and penalties associated with uncertain tax positions as a component of income tax expense in the Condensed Consolidated Statement of Earnings.

It is anticipated that the amount of unrecognized tax benefits will change in the next 12 months; however, these changes are not expected to have a significant impact on the results of operations, cash flows or the financial position of the Company.

The tax years 2005 through 2007 remain open to examination by the Internal Revenue Service. The major state taxing jurisdictions applicable to the Company remain open from 2004 through 2007.

12. Segment Information

The Company has two reportable segments, the Mylan Segment and the Matrix Segment. The Mylan Segment primarily develops, manufactures, sells and distributes generic or branded generic pharmaceutical products in tablet, capsule or transdermal patch form, while the Matrix Segment engages mainly in the manufacture and sale of active pharmaceutical ingredients APIs and the distribution of branded generic products. Additionally, certain general and administrative expenses, as well as litigation settlements, and non-operating income and expenses are reported in Corporate/Other.

The Company's chief operating decision maker evaluates the performance of its reportable segments based on net revenues and segment earnings from operations. Items below the earnings from operations line of the Condensed Consolidated Statements of Earnings are not presented by segment, since they are excluded from the measure of segment profitability reviewed by the Company's chief operating decision maker. The Company does not report depreciation expense, total assets and capital expenditures by segment as such information is not used by the chief operating decision maker.

The accounting policies of the segments are the same as those described in the Summary of Significant Accounting Policies included in our Annual Report on Form 10-K. Intersegment revenues are accounted for at current market values.

Table of Contents**MYLAN LABORATORIES INC. AND SUBSIDIARIES****Notes to Condensed Consolidated Financial Statements (Continued)**

The table below presents segment information for the three months ended June 30, 2007 and 2006 and provides a reconciliation of segment information to total consolidated information. For the Mylan and Matrix Segments, segment earnings from operations (Segment profitability (loss)) represents segment gross profit less direct research and development expenses and direct selling, general and administrative expenses.

Three Months Ended June 30, 2007	Mylan Segment	Matrix Segment	Corporate/Other(1)	Consolidated
	(In thousands)			
Intersegment revenues	\$	\$ 9,169	\$ (9,169)	\$
Third-party net revenues	451,406	91,303		542,709
Segment profitability (loss)	251,310	(17,283)	(45,953)	188,074

Three Months Ended June 30, 2006	Mylan Segment	Matrix Segment	Corporate/Other(1)	Consolidated
	(In thousands)			
Intersegment revenues	\$	\$	\$	\$
Third-party net revenues	348,789			348,789
Segment profitability (loss)	155,298		(38,149)	117,149

(1) Includes corporate overhead, intercompany eliminations and charges not directly attributable to segments.

13. Contingencies

While it is not possible to determine with any degree of certainty the ultimate outcome of the following legal proceedings, the Company believes that it has meritorious defenses with respect to the claims asserted against it and intends to vigorously defend its position. An adverse outcome in any of these proceedings could have a material adverse effect on the Company's financial position and results of operations.

Omeprazole

In fiscal 2001, Mylan Pharmaceuticals Inc. (MPI), a wholly-owned subsidiary of Mylan Laboratories Inc. (Mylan Labs), filed an Abbreviated New Drug Application (ANDA) seeking approval from the U.S. Food and Drug Administration (FDA) to manufacture, market and sell omeprazole delayed-release capsules and made Paragraph IV certifications to several patents owned by AstraZeneca PLC (AstraZeneca) that were listed in the FDA's Orange Book. On September 8, 2000, AstraZeneca filed suit against MPI and Mylan Labs in the U.S. District Court for the Southern District of New York alleging infringement of several of AstraZeneca's patents. On May 29, 2003, the FDA approved MPI's ANDA for the 10 mg and 20 mg strengths of omeprazole delayed-release capsules, and, on August 4, 2003, Mylan Labs announced that MPI had commenced the sale of omeprazole 10 mg and 20 mg delayed-release capsules. AstraZeneca then amended the pending lawsuit to assert claims against Mylan Labs and MPI and filed a separate

lawsuit against MPI's supplier, Esteve Quimica S.A. (Esteve), for unspecified money damages and a finding of willful infringement, which could result in treble damages, injunctive relief, attorneys' fees, costs of litigation and such further relief as the court deems just and proper. MPI has certain indemnity obligations to Esteve in connection with this litigation. MPI, Esteve and the other generic manufacturers who are co-defendants in the case filed motions for summary judgment of non-infringement and patent invalidity. On January 12, 2006, those motions were denied. On May 31, 2007, the district court ruled in Mylan's and Esteve's favor by finding that the asserted patents were not infringed by Mylan's/Esteve's products. On July 18, 2007, AstraZeneca appealed the decision to the United States Court of Appeals for the Federal Circuit.

Lorazepam and Clorazepate

On June 1, 2005, a jury verdict was rendered against Mylan Labs and MPI in the U.S. District Court for the District of Columbia (D.C.) in the amount of approximately \$12,000 which has been accrued for by the Company.

Table of Contents

MYLAN LABORATORIES INC. AND SUBSIDIARIES

Notes to Condensed Consolidated Financial Statements (Continued)

The jury found Mylan willfully violated Massachusetts, Minnesota and Illinois state antitrust laws in connection with API supply agreements entered into between the Company and its API supplier and broker for two drugs, lorazepam and clorazepate, in 1997, and subsequent price increases on these drugs in 1998. The case was brought by four health insurers who opted out of earlier class action settlements agreed to by the Company in 2001 and represents the last remaining claims relating to Mylan's 1998 price increases for lorazepam and clorazepate. In post-trial filings, the plaintiffs have requested that the verdict be trebled. Plaintiffs are also seeking an award of attorneys' fees, litigation costs and interest on the judgment in unspecified amounts. In total, the plaintiffs have moved for judgments that could result in a liability of approximately \$69,000 for Mylan (not including the request for attorney's fees and costs). The Company filed a motion for judgment as a matter of law, a motion for a new trial, a motion to dismiss two of the insurers and a motion to reduce the verdict. On December 20, 2006, the Company's motion for judgment as a matter of law and motion for a new trial were denied. A hearing on the pending post-trial motions took place on February 28, 2007. The Company intends to appeal to the U.S. Court of Appeals for the D.C. Circuit.

Pricing and Medicaid Litigation

On June 26, 2003, MPI and UDL Laboratories Inc. (UDL), a subsidiary of Mylan Labs, received requests from the U.S. House of Representatives Energy and Commerce Committee (the Committee) seeking information about certain products sold by MPI and UDL in connection with the Committee's investigation into pharmaceutical reimbursement and rebates under Medicaid. MPI and UDL cooperated with this inquiry and provided information in response to the Committee's requests in 2003. Several states' attorneys general (AG) have also sent letters to MPI, UDL and Mylan Bertek, demanding that those companies retain documents relating to Medicaid reimbursement and rebate calculations pending the outcome of unspecified investigations by those AGs into such matters. In addition, in July 2004, Mylan Labs received subpoenas from the AGs of California and Florida in connection with civil investigations purportedly related to price reporting and marketing practices regarding various drugs. As noted below, both California and Florida subsequently filed suits against Mylan, and the Company believes any further requests for information and disclosures will be made as part of that litigation.

Beginning in September 2003, Mylan Labs, MPI and/or UDL, together with many other pharmaceutical companies, have been named in a series of civil lawsuits filed by state AGs and municipal bodies within the state of New York alleging generally that the defendants defrauded the state Medicaid systems by allegedly reporting Average Wholesale Prices (AWP) and/or Wholesale Acquisition Costs that exceeded the actual selling price of the defendants' prescription drugs. To date, Mylan Labs, MPI and/or UDL have been named as defendants in substantially similar civil lawsuits filed by the AGs of Alabama, Alaska, California, Florida, Hawaii, Idaho, Illinois, Kentucky, Massachusetts, Mississippi, Missouri, South Carolina, Texas and Wisconsin and also by the city of New York and approximately 40 counties across New York State. Several of these cases have been transferred to the AWP multi-district litigation proceedings pending in the U.S. District Court for the District of Massachusetts for pretrial proceedings. Others of these cases will likely be litigated in the state courts in which they were filed. Each of the cases seeks an unspecified amount in money damages, civil penalties and/or treble damages, counsel fees and costs, and injunctive relief. In each of these matters, with the exception of Florida, Idaho, South Carolina AG and Texas actions and the actions brought by various counties in New York, excluding the actions brought by Erie, Oswego and Schenectady counties, Mylan Labs, MPI and/or UDL have answered the respective complaints denying liability. Mylan Labs and its subsidiaries intend to defend each of these actions vigorously.

In addition by letter dated January 12, 2005, MPI was notified by the U.S. Department of Justice of an investigation concerning MPI's calculations of Medicaid drug rebates. MPI is cooperating fully with the government's investigation.

Table of Contents

MYLAN LABORATORIES INC. AND SUBSIDIARIES

Notes to Condensed Consolidated Financial Statements (Continued)

Modafinil Antitrust Litigation and FTC Inquiry

Beginning in April 2006, Mylan Labs, along with four other drug manufacturers, has been named in a series of civil lawsuits filed in the Eastern District of Pennsylvania by a variety of plaintiffs purportedly representing direct and indirect purchasers of the drug modafinil and one action brought by Apotex, Inc., a manufacturer of generic drugs seeking approval to market a generic modafinil product. These actions allege violations of federal and state laws in connection with the defendants' settlement of patent litigation relating to modafinil. These actions are in their preliminary stages, and motions to dismiss each action are pending. Mylan Labs intends to defend each of these actions vigorously. In addition, by letter dated July 11, 2006, Mylan was notified by the U.S. Federal Trade Commission (FTC) of an investigation relating to the settlement of the modafinil patent litigation. In its letter, the FTC requested certain information from Mylan Labs, MPI and Mylan Technologies Inc. pertaining to the patent litigation and the settlement thereof. On March 29, 2007, the FTC issued a subpoena, and on April 26, 2007, the FTC issued a civil investigative demand to Mylan Labs requesting additional information from the Company relating to the investigation. Mylan is cooperating fully with the government's investigation and its outstanding requests for information.

Other Litigation

The Company is involved in various other legal proceedings that are considered normal to its business. While it is not feasible to predict the ultimate outcome of such other proceedings, the Company believes that the ultimate outcome of such other proceedings will not have a material adverse effect on its financial position or results of operations.

14. Guarantor Financial Statements

Each of the Company's wholly-owned domestic subsidiaries, except a captive insurance company, has guaranteed, on a full, unconditional and joint and several basis, the Company's performance under the Notes (collectively, the Guarantor Subsidiaries). Matrix is not a guarantor of the Notes. There are certain restrictions under the Notes indenture on the ability of the Company and the Guarantor Subsidiaries to receive or distribute funds in the form of cash dividends, loans or advances. The following combined financial data provides information regarding the financial position, results of operations and cash flows of the Guarantor Subsidiaries (condensed consolidating financial data). Separate financial statements and other disclosures concerning the Guarantor Subsidiaries are not presented because management has determined that such information would not be material to the holders of the debt.

Table of Contents**MYLAN LABORATORIES INC. AND SUBSIDIARIES****Notes to Condensed Consolidated Financial Statements (Continued)**
GUARANTOR SUBSIDIARIES**CONDENSED CONSOLIDATING BALANCE SHEETS**

June 30, 2007 (In thousands)	Mylan Labs	Guarantor Subs	Non- Guarantor Subs	Consolidating and Eliminating Entries	Consolidated
Assets					
Current assets:					
Cash and cash equivalents	\$ 1,228,533	\$ 2,959	\$ 77,444	\$ 6,621	\$ 1,315,557
Marketable securities	144,419		30,466		174,885
Accounts receivable, net	9,972	315,887	87,433	(12,221)	401,071
Inventories		331,429	103,047	(2,128)	432,348
Deferred income tax benefits	27,425	132,325	2,124		161,874
Prepaid and other current assets	125,858	13,193	49,367	(52,129)	136,289
Total current assets	1,536,207	795,793	349,881	(59,857)	2,622,024
Intercompany receivables, net	(452,148)	1,062,013	(776,842)	166,977	
Property, plant and equipment, net	77,680	459,716	169,668		707,064
Intangible assets, net		86,073	257,735		343,808
Goodwill		102,578	507,670		610,248
Deferred income tax benefit	44,851	569	582		46,002
Other assets	68,153	9,203	69,019		146,375
Investments in subsidiaries	2,164,976			(2,164,976)	
Total assets	\$ 3,439,719	\$ 2,515,945	\$ 577,713	\$ (2,057,856)	\$ 4,475,521
Liabilities and Shareholders Equity					
Current liabilities:					
Liabilities					
Trade accounts payable	\$ 788	\$ 41,061	\$ 105,563	\$ (601)	\$ 146,811
Short-term borrowings			107,315		\$ 107,315
Income taxes payable	(34,749)	124,156	3,907	(1,756)	91,558
Current portion of long-term obligations	3,352		127,404		130,756
Cash dividends payable	14,923				14,923
Other current liabilities	190,265	107,395	91,443	(51,499)	337,604

Edgar Filing: MYLAN LABORATORIES INC - Form 10-Q

Total current liabilities	174,579	272,612	435,632	(53,856)	828,967
Deferred revenue		102,995			102,995
Long-term debt	1,550,000		106,064		1,656,064
Deferred income tax liability	(16,232)	(988)	102,602		85,382
Other long-term obligations	18,238	4,600	18,092	(463)	40,467
Total liabilities	1,726,585	379,219	662,390	(54,319)	2,713,875
Minority interest			37,454	(787)	36,667
Shareholders' equity					
Preferred stock					
Common stock	169,856	7,493	210	(7,703)	169,856
Additional paid-in capital	975,565	600,176	10,596	(609,893)	976,444
Retained earnings	2,156,667	1,529,047	(143,893)	(1,385,154)	2,156,667
Accumulated other comprehensive earnings	(680)	10	10,956		10,286
	3,301,408	2,136,726	(122,131)	(2,002,750)	3,313,253
Less:					
Treasury stock at cost	(1,588,274)				(1,588,274)
Total shareholders' equity	1,713,134	2,136,726	(122,131)	(2,002,750)	1,724,979
Total liabilities and shareholders' equity	\$ 3,439,719	\$ 2,515,945	\$ 577,713	\$ (2,057,856)	\$ 4,475,521

Table of Contents**MYLAN LABORATORIES INC. AND SUBSIDIARIES****Notes to Condensed Consolidated Financial Statements (Continued)****GUARANTOR SUBSIDIARIES****CONDENSED CONSOLIDATING BALANCE SHEETS**

March 31, 2007 (In thousands)	Mylan Labs	Guarantor Subs	Non- Guarantor Subs	Consolidating and Eliminating Entries	Consolidated
Assets					
Current assets:					
Cash and cash equivalents	\$ 1,146,380	\$ 21,689	\$ 84,312	\$ (16)	\$ 1,252,365
Marketable securities	143,220		30,987		174,207
Accounts receivable, net	10,708	262,024	79,712	(2,150)	350,294
Inventories		324,767	108,096	(3,752)	429,111
Other current assets	5,400	158,488	47,129	(4,950)	206,067
Total current assets	1,305,708	766,968	350,236	(10,868)	2,412,044
Intercompany receivables, net	(390,417)	1,009,683	(776,231)	156,965	
Property, plant and equipment, net	16,741	510,853	159,145		686,739
Intangible assets, net		89,321	263,459		352,780
Goodwill		102,579	510,163		612,742
Other assets	162,480	12,191	64,891	(50,000)	189,562
Investments in subsidiaries	2,007,547			(2,007,547)	
Total assets	\$ 3,102,059	\$ 2,491,595	\$ 571,663	\$ (1,911,450)	\$ 4,253,867
Liabilities and Shareholders Equity					
Current liabilities:					
Trade accounts payable	\$ 302	\$ 56,617	\$ 105,532	\$ (2,165)	\$ 160,286
Income taxes payable	(177,857)	252,404	5,464	(1,624)	78,387
Current portion of long-term obligations	3,352		121,430		124,782
Cash dividends payable	14,902				14,902
Other current liabilities	61,312	114,255	148,295	(1,684)	322,178
Total current liabilities	(97,989)	423,276	380,721	(5,473)	700,535
Deferred revenue		90,673			90,673
Long-term debt	1,550,000		104,932		1,654,932

Edgar Filing: MYLAN LABORATORIES INC - Form 10-Q

Other long-term obligations	2,700	1,309	161,651	(50,000)	115,660
Minority interest			44,469	(1,262)	43,207
Shareholders' equity					
Preferred stock					
Common stock	169,681	7,494	210	(7,704)	169,681
Additional paid-in capital	962,415	593,831	10,048	(603,548)	962,746
Retained earnings	2,103,282	1,375,003	(131,540)	(1,243,463)	2,103,282
Accumulated other comprehensive earnings	363	9	1,172		1,544
	3,235,741	1,976,337	(120,110)	(1,854,715)	3,237,253
Less:					
Treasury stock at cost	(1,588,393)				(1,588,393)
Total shareholders' equity	1,647,348	1,976,337	(120,110)	(1,854,715)	1,648,860
Total liabilities and shareholders' equity	\$ 3,102,059	\$ 2,491,595	\$ 571,663	\$ (1,911,450)	\$ 4,253,867

Table of Contents**MYLAN LABORATORIES INC. AND SUBSIDIARIES****Notes to Condensed Consolidated Financial Statements (Continued)**
GUARANTOR SUBSIDIARIES**CONDENSED CONSOLIDATING STATEMENTS OF EARNINGS**

Three Months Ended June 30, 2007 (In thousands)	Mylan Labs	Guarantor Subs	Non- Guarantor Subs	Consolidating and Eliminating Entries	Consolidated
Revenues:					
Net revenues	\$	\$ 451,406	\$ 100,472	\$ (9,169)	\$ 542,709
Other revenues		3,612			3,612
Total revenues		455,018	100,472	(9,169)	546,321
Cost of sales		167,783	84,091	(2,261)	249,613
Gross profit		287,235	16,381	(6,908)	296,708
Operating expenses:					
Research and development	2,555	27,412	8,273	(6,520)	31,720
Selling, general & administrative	37,994	22,048	16,872		76,914
Total operating expenses	40,549	49,460	25,145	(6,520)	108,634
(Loss) earnings from operations	(40,549)	237,775	(8,764)	(388)	188,074
Interest expense	17,926		4,993		22,919
Other (expense) income, net	(41,995)	674	3,525	(843)	(38,639)
(Loss) earnings before income taxes, minority interest and equity in earnings of subsidiaries	(100,470)	238,449	(10,232)	(1,231)	126,516
Provision for income taxes	(1,059)	50,136	262	(132)	49,207
(Loss) earnings before minority interest and equity in earnings of subsidiaries	(99,411)	188,313	(10,494)	(1,099)	77,309
Minority interest			(137)		(137)
(Loss) earnings before equity in earnings of subsidiaries	(99,411)	188,313	(10,357)	(1,099)	77,446
Equity in earnings of subsidiaries	179,138	(9,644)	1,131	(168,344)	2,281

Net earnings (loss)	\$ 79,727	\$ 178,669	\$ (9,226)	\$ (169,443)	\$ 79,727
---------------------	-----------	------------	------------	--------------	-----------

Table of Contents**MYLAN LABORATORIES INC. AND SUBSIDIARIES****Notes to Condensed Consolidated Financial Statements (Continued)
GUARANTOR SUBSIDIARIES****CONDENSED CONSOLIDATING STATEMENTS OF EARNINGS**

Three Months Ended June 30, 2006 (In thousands)	Mylan Labs	Guarantor Subs	Non- Guarantor Subs	Consolidating and Eliminating Entries	Consolidated
Revenues:					
Net revenues	\$	\$ 348,789	\$	\$	\$ 348,789
Other revenues		7,351			7,351
Total revenues		356,140			356,140
Cost of sales		168,813		(873)	167,940
Gross profit		187,327		873	188,200
Operating expenses:					
Research and development	2,591	18,634			21,225
Selling, general & administrative	29,665	19,646	515		49,826
Total operating expenses	32,256	38,280	515		71,051
(Loss) earnings from operations	(32,256)	149,047	(515)	873	117,149
Interest expense	10,359				10,359
Other income, net	3,934	256	1,229	(873)	4,546
(Loss) earnings before income taxes and equity in earnings of subsidiaries	(38,681)	149,303	714		111,336
Provision for income taxes	5,368	35,169	250		40,787
(Loss) earnings before equity in earnings of subsidiaries	(44,049)	114,134	464		70,549
Equity in earnings of subsidiaries	119,636	5,038		(119,636)	5,038
Net earnings	\$ 75,587	\$ 119,172	\$ 464	\$ (119,636)	\$ 75,587

Table of Contents**MYLAN LABORATORIES INC. AND SUBSIDIARIES****Notes to Condensed Consolidated Financial Statements (Continued)
GUARANTOR SUBSIDIARIES****CONDENSED CONSOLIDATING STATEMENTS OF CASH FLOWS**

Three Months Ended June 30, 2007 (In thousands)	Mylan Labs	Guarantor Subs	Non- Guarantor Subs	Eliminating	Consolidated
Cash flows (used in) provided by operations:	\$ (35,376)	\$ 105,657	\$ 7,633	\$ 6,637	\$ 84,551
Cash flows from investing activities:					
Capital expenditures	(3,566)	(17,740)	(6,563)		(27,869)
Purchase of marketable securities	(71,241)		(15,029)		(86,270)
Proceeds from sale of marketable securities	68,708		14,494		83,202
Other items, net		(693)	387		(306)
Net cash used in investing activities	(6,099)	(18,433)	(6,711)		(31,243)
Cash flows from financing activities:					
Cash dividends paid	(14,902)				(14,902)
Excess tax benefit from stock-based compensation	2,082				2,082
Proceeds from exercise of stock options	5,094		987		6,081
Change in outstanding checks in excess of cash in disbursement accounts		18,008			18,008
Change in short-term borrowings, net			(3,824)		(3,824)
Other items, net			(1,572)		(1,572)
Transfer from (to) affiliates	131,354	(123,962)	(7,392)		
Net cash provided by (used in) financing activities	123,628	(105,954)	(11,801)		5,873
Effect on cash of changes in exchange rates			4,011		4,011
Net increase (decrease) in cash and cash equivalents	82,153	(18,730)	(6,868)	6,637	63,192
Cash and cash equivalents beginning of period	1,146,380	21,689	84,312	(16)	1,252,365

Cash and cash equivalents end of period \$ 1,228,533 \$ 2,959 \$ 77,444 \$ 6,621 \$ 1,315,557

Table of Contents**MYLAN LABORATORIES INC. AND SUBSIDIARIES****Notes to Condensed Consolidated Financial Statements (Continued)
GUARANTOR SUBSIDIARIES****CONDENSED CONSOLIDATING STATEMENTS OF CASH FLOWS**

Three Months Ended June 30, 2006 (In thousands)	Mylan Labs	Guarantor Subs	Non- Guarantor Subs	Eliminating	Consolidated
Cash flows (used in) provided by operations:	\$ (39,004)	\$ 138,127	\$ 1,371	\$ (7,605)	\$ 92,889
Cash flows from investing activities:					
Capital expenditures	(2,064)	(25,653)			(27,717)
Purchase of marketable securities		(178,436)	(13,617)		(192,053)
Proceeds from sale of marketable securities		134,422	10,258		144,680
Other items, net		(159)			(159)
Net cash used in investing activities	(2,064)	(69,826)	(3,359)		(75,249)
Cash flows from financing activities:					
Cash dividends paid	(12,605)				(12,605)
Payment of financing fees	(632)				(632)
Excess tax benefit from stock-based compensation	700				700
Proceeds from exercise of stock options	6,301				6,301
Change in outstanding checks in excess of cash in disbursement accounts		(7,605)			(7,605)
Transfer from (to) affiliates	52,836	(52,836)			
Other items, net					
Net cash provided by (used in) financing activities	46,600	(60,441)			(13,841)
Net increase (decrease) in cash and cash equivalents	5,532	7,860	(1,988)	(7,605)	3,799
Cash and cash equivalents beginning of period	4,911	128,191	9,417	7,605	150,124
Cash and cash equivalents end of period	\$ 10,443	\$ 136,051	\$ 7,429	\$	\$ 153,923

Table of Contents

ITEM 2. *MANAGEMENT'S DISCUSSION AND ANALYSIS OF RESULTS OF OPERATIONS AND FINANCIAL CONDITION*

The following discussion and analysis addresses material changes in the results of operations and financial condition of Mylan Laboratories Inc. and Subsidiaries (the Company, Mylan or we) for the periods presented. This discussion and analysis should be read in conjunction with the Consolidated Financial Statements, the related Notes to Consolidated Financial Statements and Management's Discussion and Analysis of Results of Operations and Financial Condition included in the Company's Annual Report on Form 10-K for the fiscal year ended March 31, 2007, the unaudited interim Condensed Consolidated Financial Statements and related Notes included in Item 1 of this Report on Form 10-Q (Form 10-Q) and the Company's other SEC filings and public disclosures.

This Form 10-Q may contain forward-looking statements. These statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements may include, without limitation, statements about the Company's market opportunities, strategies, competition and expected activities and expenditures, and at times may be identified by the use of words such as may, will, could, should, would, project, believe, anticipate, expect, plan, estimate, forecast, potential, intend, continue words or comparable words. Forward-looking statements inherently involve risks and uncertainties. Accordingly, actual results may differ materially from those expressed or implied by these forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to, the risks described below under Risk Factors in Part II, Item 1A. The Company undertakes no obligation to update any forward-looking statements for revisions or changes after the date of this Form 10-Q.

Overview

Mylan's financial results for the three months ended June 30, 2007, included total revenues of \$546.3 million, net earnings of \$79.7 million and earnings per diluted share of \$0.32. Comparatively, the three months ended June 30, 2006, included total revenues of \$356.1 million, net earnings of \$75.6 million and earnings per diluted share of \$0.35. This represents an increase of 53% in total revenues and 5% in net earnings and a decrease of 9% in earnings per diluted share when compared to the same prior year period. Since the first quarter of fiscal 2007, Mylan issued 26.2 million shares of its common stock in an equity offering in March 2007, and sold approximately 8.1 million shares to certain selling shareholders of Matrix Laboratories Limited (Matrix) in the acquisition, which was completed during the Company's fourth quarter of fiscal 2007.

Included in diluted earnings per share for the first quarter of fiscal 2008 was a charge of \$0.15 per diluted share with respect to a deal-contingent foreign currency option contract entered into with respect to the pending acquisition of Merck KGaA's generic business (Merck Generics). On May 12, 2007, Mylan and Merck KGaA announced the signing of a definitive agreement under which Mylan, subject to regulatory review in the United States and other customary closing conditions, will acquire Merck Generics for 4.9 billion (approximately \$6.7 billion) in an all-cash transaction. In conjunction with the Merck Generics transaction, Mylan entered into a deal-contingent foreign currency option contract in order to mitigate the risk of foreign currency exposure. The contract is contingent upon the closing of this acquisition, and the premium of approximately \$121.9 million will be paid only upon such closing. The Company accounts for this instrument under the provisions of Statement of Financial Accounting Standards (SFAS) No. 133, *Accounting for Derivative Instruments and Hedging Activities* (SFAS No. 133) (SFAS No. 133). This instrument does not qualify for hedge accounting treatment under SFAS No. 133 and, therefore, is adjusted to fair value at each reporting date with the change in the fair value of the instrument recorded in earnings.

With the addition of Matrix, Mylan now reports as two reportable segments, the Mylan Segment and the Matrix Segment . Additionally, certain general and administrative expenses, as well as litigation settlements, and non-operating income and expenses are reported in Corporate/Other. In accordance with SFAS No. 131, *Disclosures about Segments of an Enterprise and Related Information* (SFAS No. 131), information for earlier periods has been recast.

Table of Contents

The Mylan Segment had total revenues of \$455.0 million for the quarter ended June 30, 2007, and the Matrix Segment had total revenues of \$91.3 million. A more detailed discussion of the Company's financial results can be found below in the section titled Results of Operations.

Results of Operations

Quarter Ended June 30, 2007, Compared to Quarter Ended June 30, 2006

Revenues and Gross Profit

Total revenues for the current quarter increased 53% or \$190.2 million to \$546.3 million compared to \$356.1 million in the first quarter of fiscal 2007. Mylan Segment total revenues were \$455.0 million, and Matrix Segment total revenues were \$91.3 million.

For the Mylan Segment, net revenues for the current quarter increased by \$102.6 million or 29% compared to the three months ended June 30, 2006, primarily as a result of the contribution from new products, partially offset by lower volume on existing products as a result of product mix. Pricing was relatively stable compared to the prior year.

New products in the first quarter of fiscal 2008 contributed net revenues of \$124.7 million. Amlodipine accounted for \$84.0 million of new product revenue, with oxybutynin and several other recent product launches comprising the remainder. Mylan launched amlodipine in the latter part of its fiscal 2007 fourth quarter. However, because of significant uncertainties surrounding the Food and Drug Administration's approval of additional amlodipine abbreviated new drug applications (ANDAs) we were unable to reasonably estimate the amount of potential price adjustments that would occur as a result of the additional approvals. As a result, revenues on shipments of amlodipine are deferred until such uncertainties were resolved. Such uncertainties are resolved upon our customers' sale of this product. There are currently 15 competitors with approved ANDAs to sell amlodipine, and the market dynamics continue to change. As such, these uncertainties continue to exist and Mylan continues to defer the recognition of amlodipine revenue until the uncertainties are resolved.

Fentanyl, which continues to be the only ANDA-approved, AB-rated generic alternative to Duragesic® on the market, accounted for approximately 16% of Mylan Segment net revenues for the three months ended June 30, 2007. For the Mylan Segment, total doses shipped increased from the same prior year period by approximately 4% to 3.6 billion doses on a year over year basis.

Net revenues for the Matrix Segment were \$100.5 million, of which \$91.3 million represented third-party sales. Approximately 65% of the Matrix Segment's third-party net revenues comes from the sale of API and intermediates and approximately 25% mainly from the distribution of branded generic products in Europe. Intersegment revenue was derived from API sales to the Mylan Segment primarily in conjunction with the launch of amlodipine which is a vertically integrated product, as well as revenue earned through intersegment product development agreements.

Consolidated gross profit increased 58% or \$108.5 million to \$296.7 million from \$188.2 million, and gross margins increased to 54.3% from 52.8%. Included in gross profit for the first quarter of fiscal 2008 were purchase accounting related items of approximately \$14.9 million, which consisted of incremental amortization related to the intangible assets and the amortization of the inventory step-up associated with the Matrix acquisition. Excluding such items, consolidated gross margins were 57.0%.

For the Mylan Segment, gross profit was \$289.2 million compared to \$188.2 million, while gross margins increased to 63.6% from 52.8%. A significant portion of gross profit, as well as the increase in gross margins, was comprised of new products, including amlodipine and fentanyl. Fentanyl contributes margins well in excess of most other products

in our portfolio, excluding new products. Absent any changes to market dynamics or significant new competition for fentanyl, the Company expects the product to continue to be a significant contributor to sales and gross profit. Products generally contribute most significantly to gross margin at the time of their launch and even more so in periods of market exclusivity. As is typical in the generic industry, the entrance into the market of other generic competition generally has a negative impact on the volume and pricing of the affected products.

Table of Contents

Operating Expenses

Consolidated research and development (R&D) expense for the current quarter was \$31.7 million compared to \$21.2 million for the same period in the prior year, which represents an increase of \$10.5 million or 49%. Matrix Segment R&D expense was \$8.3 million for the three months ended June 30, 2007. Excluding Matrix, R&D expense increased by \$2.2 million or 10%. The Mylan Segment had R&D expense of \$20.9 million for the current quarter compared to \$18.6 million for the same period in the prior year. This increase is primarily the result of a higher number of clinical studies in fiscal 2008 compared to the prior year.

Selling, general and administrative (SG&A) expense for the current quarter was \$76.9 million compared to \$49.8 million for the same period in the prior year, an increase of \$27.0 million or 54%. The Matrix Segment accounted for a majority of the increase, with SG&A expense of \$16.5 million. The remainder of the increase was primarily the result of higher Corporate/Other SG&A which increased \$7.8M or 22% to \$43.4 million from \$35.6 million. The increase to Corporate/Other SG&A is due to numerous factors including higher payroll and payroll related costs, increased depreciation expense and increased consulting costs.

Interest Expense

Interest expense for the three months ended June 30, 2007 totaled \$22.9 million compared to \$10.4 million for the same period of the prior year. The increase is the result of additional debt incurred after June 30, 2006, in order to fund a portion of the Matrix acquisition as well as debt assumed in the Matrix acquisition and the issuance of the Convertible Notes in March of 2007. Included in interest expense is a commitment fee on the Revolving Credit Facility and the amortization of financing fees.

Other (Expense) Income, net

Other (expense) income, net was \$36.4 million of expense in the first quarter of fiscal 2008 compared to \$9.6 million of income in the same prior year period. The decrease is primarily the result of a non-cash mark to market unrealized loss of \$57.5 million recorded in the first quarter of fiscal 2008 on a deal-contingent foreign currency option contract entered into with respect to the pending acquisition of Merck Generics. The purpose of this foreign currency option contract is to mitigate any exchange rate risk. In accordance with SFAS No. 133, this derivative instrument is marked to market each period with any change in the fair value reported in current earnings.

Partially offsetting this charge within other (expense) income, net is interest income and income related to Mylan's equity method investees. During the quarter ended June 30, 2007, the Company recorded income from its equity method investees of \$2.3 million compared to \$5.0 million in the same prior year period. During the quarter ended June 30, 2006, Mylan received a cash payment from Somerset Pharmaceuticals, Inc. (Somerset), of which we own a 50% equity interest, of approximately \$5.5 million. The amount in excess of the carrying value of our investment in Somerset, approximately \$5.0 million, was recorded as equity income.

Income Tax Expense

The company's effective tax rate increased in the current quarter to 38.2% from 35.0% in the same period of the prior year. This increase is due primarily to the impact of losses in certain entities for which the Company could not recognize a tax benefit, which is expected to diminish over time.

Liquidity and Capital Resources

Edgar Filing: MYLAN LABORATORIES INC - Form 10-Q

Cash flows from operating activities were \$84.6 million for the three months ended June 30, 2007, resulting from net income and non-cash add-backs (including the mark to market loss on the foreign currency option contract), partially offset by the deferred tax benefit and changes in working capital items. In total, working capital as of June 30, 2007 was \$1.8 billion compared to \$1.7 billion at March 31, 2007. The most significant working capital items affecting cash were accounts receivable, which increased as a result of higher overall sales, including revenue recognized on amlodipine, and accounts payable which decreased as a result of the timing of payments.

Cash used in investing activities for the three months ended June 30, 2007, was \$31.2 million. Of the Company's \$4.5 billion of total assets at June 30, 2007, \$1.5 billion was held in cash, cash equivalents and

Table of Contents

marketable securities. Investments in marketable securities consist primarily of a variety of high credit quality debt securities, including U.S. government, state and local government and corporate obligations. These investments are highly liquid and available for working capital needs. As these instruments mature, the funds are generally reinvested in instruments with similar characteristics.

Cash provided by financing activities was \$5.9 million for the three months ended June 30, 2007, consisting primarily of proceeds from the exercise of stock options of \$6.1 million and an \$18.0 million change in the amount of outstanding checks in excess of cash in our primary disbursement accounts. The Company utilizes a cash management system under which uncleared checks in excess of the cash balance in the bank account at the end of the reporting period are shown as a book cash overdraft. The Company transfers cash on an as-needed basis to fund clearing checks. The Company does not incur any financing charges with respect to this arrangement.

Partially offsetting these cash inflows were \$14.9 million of cash dividends paid during the quarter. However, as announced on May 12, 2007, in conjunction with the contemplated acquisition of Merck Generics, the Company is suspending the dividend on its common stock.

On May 12, 2007, Mylan and Merck KGaA announced the signing of a definitive agreement under which Mylan, subject to regulatory review in the United States and other customary closing conditions, will acquire Merck's Generics for 4.9 billion (approximately \$6.7 billion) in an all-cash transaction. Mylan has obtained fully committed financing from Merrill Lynch, Citigroup, J.P. Morgan, and Goldman Sachs.

In conjunction with the Merck Generics transaction, the Company entered into a deal-contingent foreign currency option contract in order to mitigate the risk of foreign currency exposure. The contract is contingent upon the closing of this acquisition, and the premium of approximately \$121.9 million will be paid only upon such closing.

The Company is involved in various legal proceedings that are considered normal to its business (see Note 13) to the Condensed Consolidated Financial Statements. While it is not feasible to predict the outcome of such proceedings, an adverse outcome in any of these proceedings could materially affect the Company's financial position and results of operations.

The Company is actively pursuing, and is currently involved in, joint projects related to the development, distribution and marketing of both generic and brand products. Many of these arrangements provide for payments by the Company upon the attainment of specified milestones. While these arrangements help to reduce the financial risk for unsuccessful projects, fulfillment of specified milestones or the occurrence of other obligations may result in fluctuations in cash flows.

The Company is continuously evaluating the potential acquisition of products, as well as companies, as a strategic part of its future growth. Consequently, the Company may utilize current cash reserves or incur additional indebtedness to finance any such acquisitions, which could impact future liquidity.

Recent Accounting Pronouncements

In September 2006, the FASB issued SFAS No. 157, *Fair Value Measurements* (SFAS 157), which defines fair value, establishes a framework for measuring fair value in GAAP and expands disclosure about fair value measurements. The statement is effective for fiscal years beginning after November 15, 2007. The Company is currently evaluating the impact of adopting SFAS 157 on its consolidated financial statements.

In February 2007, the FASB issued SFAS No. 159, *The Fair Value Option for Financial Assets and Financial Liabilities* (SFAS 159), providing companies with an option to report selected financial assets and liabilities at fair

value. This statement is effective for fiscal years beginning after November 15, 2007. The Company is currently evaluating the impact of adopting SFAS 159 on its consolidated financial statements.

ITEM 3. *QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK*

The Company is subject to market risk primarily from changes in the market values of investments in its marketable debt securities, interest rate risk from changes in interest rates associated with its long-term debt and foreign currency exchange rate risk as a result of its pending acquisition of Merck Generics.

Table of Contents**Marketable Debt Securities**

In addition to marketable debt and equity securities, investments are made in overnight deposits, money market funds and marketable securities with maturities of less than three months. These instruments are classified as cash equivalents for financial reporting purposes and have minimal or no interest rate risk due to their short-term nature.

The following table summarizes the investments in marketable debt and equity securities which subject the Company to market risk at June 30, 2007 and March 31, 2007:

	June 30, 2007	March 31, 2007
Marketable debt securities	\$ 172,440	\$ 171,548
Marketable equity securities	2,445	2,659
	\$ 174,885	\$ 174,207

The primary objectives for the marketable debt securities investment portfolio are liquidity and safety of principal. Investments are made to achieve the highest rate of return while retaining principal. Our investment policy limits investments to certain types of instruments issued by institutions and government agencies with investment-grade credit ratings. At June 30, 2007, the Company had invested \$172.4 million in marketable debt securities, of which \$22.2 million will mature within one year and \$150.2 million will mature after one year. The short duration to maturity creates minimal exposure to fluctuations in market values for investments that will mature within one year. However, a significant change in current interest rates could affect the market value of the remaining \$150.2 million of marketable debt securities that mature after one year. A 5% change in the market value of the marketable debt securities that mature after one year would result in a \$7.5 million change in marketable debt securities.

Long-Term Debt

On July 21, 2005, the Company issued \$500.0 million in Senior Notes with fixed interest rates (which were exchanged for registered notes, as described previously) and, on July 24, 2006, entered into a five-year \$700.0 million senior unsecured revolving credit facility (the 2006 Credit Facility). On March 26, 2007, Mylan and its wholly-owned indirect subsidiary Euro Mylan B.V. (Euro Mylan) entered into a credit agreement with a syndicate of bank lenders for a \$750.0 million senior unsecured credit facility (the 2007 Credit Facility), including (i) a multicurrency revolving credit facility (the Revolving Credit Facility) in an aggregate amount of up to a U.S. Dollar equivalent of \$300.0 million due July 24, 2011, and (ii) a term loan facility (the Term Loan Facility) denominated in U.S. Dollars in aggregate amount of up to \$450.0 million due December 26, 2011. The Company borrowed \$450.0 million under the Term Loan Facility and used the proceeds to repay the revolving loans outstanding under the Company's existing 2006 Credit Facility. The interest rate in effect at June 30, 2007 on the outstanding borrowings under the Term Loan Facility was 6.07%.

On March 1, 2007, Mylan entered into a Purchase Agreement (the Convertible Notes Purchase Agreement) relating to the sale by the Company of \$600.0 million aggregate principal amount of the Company's 1.25% Senior Convertible Notes due 2012 (the Convertible Notes). The Convertible Notes bear interest at a rate of 1.25% per year, accruing from March 7, 2007. Interest is payable semiannually in arrears on March 15 and September 15 of each year, beginning September 15, 2007. The Convertible Notes will mature on March 15, 2012, subject to earlier repurchase or conversion. The Convertible Notes have an initial conversion rate of 44.5931 shares of common stock per \$1,000 principal amount (equivalent to an initial conversion price of approximately \$22.43 per share), subject to adjustment.

Matrix's long-term debt included two term loan borrowings both of which are denominated in Euros. Matrix's effective interest rate for these loans is Euro Interbank Offered Rate (Euribor) plus 110 basis points for the first facility (Facility A) of 82.50 million and Euribor plus 129 basis points for the second facility (Facility B) of 82.50 million for the period ended June 30, 2007. Subsequent to June 30, 2007, Facility A was repaid.

Generally, the fair market value of fixed interest rate debt will decrease as interest rates rise and increase as interest rates fall. As of June 30, 2007, the fair value of our Convertible Notes was approximately \$581.4 million.

Table of Contents

The carrying value of our Senior Notes, our Term Loan facility, and Matrix's term loan borrowings approximated fair value. A 10% change in interest rates on the variable rate debt would result in a change in interest expense of approximately \$3.9 million per year.

Deal-Contingent Foreign Currency Option Contract

In conjunction with the Merck Generics transaction, the Company entered into a deal-contingent foreign currency option contract in order to mitigate the risk of foreign currency exposure related to the Euro denominated purchase price. The contract is contingent upon the closing of this acquisition, and the premium of approximately \$121.9 million will be paid only upon such closing. The value of the foreign currency option contract fluctuates depending on the value of the U.S. dollar compared to the Euro. On June 30, 2007, the mark to market value of this foreign currency option contract resulted in a loss of \$57.5 million.

ITEM 4. CONTROLS AND PROCEDURES

An evaluation was performed under the supervision and with the participation of the Company's management, including the Chief Executive Officer and the Chief Financial Officer, of the effectiveness of the design and operation of the Company's disclosure controls and procedures as of June 30, 2007. Based upon that evaluation, the Chief Executive Officer and the Chief Financial Officer concluded that the Company's disclosure controls and procedures were effective. During the three months ended June 30, 2007, the Company began utilizing SAP enterprise resource planning (ERP) system at Mylan Pharmaceuticals Inc. and its corporate offices. No other changes in the Company's internal control over financial reporting occurred during the fiscal quarter ended June 30, 2007 that has materially affected, or is reasonably likely to materially affect, the Company's internal control over financial reporting.

PART II. OTHER INFORMATION

ITEM 1. LEGAL PROCEEDINGS

While it is not possible to determine with any degree of certainty the ultimate outcome of the following legal proceedings, the Company believes that it has meritorious defenses with respect to the claims asserted against it and intends to vigorously defend its position. An adverse outcome in any of these proceedings could have a material adverse effect on the Company's financial position and results of operations.

Omeprazole

In fiscal 2001, Mylan Pharmaceuticals Inc. (MPI), a wholly-owned subsidiary of Mylan Labs, filed an Abbreviated New Drug Application (ANDA) seeking approval from the FDA to manufacture, market and sell omeprazole delayed-release capsules and made Paragraph IV certifications to several patents owned by AstraZeneca PLC (AstraZeneca) that were listed in the U.S. Food and Drug Administration's (FDA) Orange Book. On September 8, 2000, AstraZeneca filed suit against MPI and Mylan Labs in the U.S. District Court for the Southern District of New York alleging infringement of several of AstraZeneca's patents. On May 29, 2003, the FDA approved MPI's ANDA for the 10 mg and 20 mg strengths of omeprazole delayed-release capsules, and, on August 4, 2003, Mylan Labs announced that MPI had commenced the sale of omeprazole 10 mg and 20 mg delayed-release capsules. AstraZeneca then amended the pending lawsuit to assert claims against Mylan Labs and MPI and filed a separate lawsuit against MPI's supplier, Esteve Quimica S.A. (Esteve), for unspecified money damages and a finding of willful infringement, which could result in treble damages, injunctive relief, attorneys' fees, costs of litigation and such further relief as the court deems just and proper. MPI has certain indemnity obligations to Esteve in connection with this litigation. MPI, Esteve and the other generic manufacturers who are co-defendants in the case filed motions for summary judgment of non-infringement and patent invalidity. On January 12, 2006, those motions were denied. On May 31, 2007, the

district court ruled in Mylan's and Esteve's favor by finding that the asserted patents were not infringed by Mylan's/Esteve's products. On July 18, 2007, Astra appealed the decision to the United States Court of Appeals for the Federal Circuit.

Table of Contents

Lorazepam and Clorazepate

On June 1, 2005, a jury verdict was rendered against Mylan Labs and MPI in the U.S. District Court for the District of Columbia (D.C.) in the amount of approximately \$12.0 million which has been accrued for by the Company. The jury found Mylan willfully violated Massachusetts, Minnesota and Illinois state antitrust laws in connection with Active Pharmaceutical Ingredient (API) supply agreements entered into between the Company and its API supplier and broker for two drugs, lorazepam and clorazepate, in 1997, and subsequent price increases on these drugs in 1998. The case was brought by four health insurers that opted out of earlier class action settlements agreed to by the Company in 2001 and represents the last remaining claims relating to Mylan s 1998 price increases for lorazepam and clorazepate. In post-trial filings, the plaintiffs have requested that the verdict be trebled. Plaintiffs are also seeking an award of attorneys fees, litigation costs and interest on the judgment in unspecified amounts. In total, the plaintiffs have moved for judgments that could result in a liability of approximately \$69 million for Mylan (not including the request for attorney s fees and costs). The Company filed a motion for judgment as a matter of law, a motion for a new trial, a motion to dismiss two of the insurers and a motion to reduce the verdict. On December 20, 2006, the Company s motion for judgment as a matter of law and motion for a new trial were denied. A hearing on the pending post-trial motions took place on February 28, 2007. The Company intends to appeal to the U.S. Court of Appeals for the D.C. Circuit.

Pricing and Medicaid Litigation

On June 26, 2003, MPI and UDL Laboratories Inc. (UDL), a subsidiary of Mylan Labs, received requests from the U.S. House of Representatives Energy and Commerce Committee (the Committee) seeking information about certain products sold by MPI and UDL in connection with the Committee s investigation into pharmaceutical reimbursement and rebates under Medicaid. MPI and UDL cooperated with this inquiry and provided information in response to the Committee s requests in 2003. Several states attorneys general (AG) have also sent letters to MPI, UDL and Mylan Bertek, demanding that those companies retain documents relating to Medicaid reimbursement and rebate calculations pending the outcome of unspecified investigations by those AGs into such matters. In addition, in July 2004, Mylan Labs received subpoenas from the AGs of California and Florida in connection with civil investigations purportedly related to price reporting and marketing practices regarding various drugs. As noted below, both California and Florida subsequently filed suits against Mylan, and the Company believes any further requests for information and disclosures will be made as part of that litigation.

Beginning in September 2003, Mylan Labs, MPI and/or UDL, together with many other pharmaceutical companies, have been named in a series of civil lawsuits filed by state AGs and municipal bodies within the state of New York alleging generally that the defendants defrauded the state Medicaid systems by allegedly reporting Average Wholesale Prices (AWP) and/or Wholesale Acquisition Costs that exceeded the actual selling price of the defendants prescription drugs. To date, Mylan Labs, MPI and/or UDL have been named as defendants in substantially similar civil lawsuits filed by the AGs of Alabama, Alaska, California, Florida, Hawaii, Idaho, Illinois, Kentucky, Massachusetts, Mississippi, Missouri, South Carolina, Texas and Wisconsin and also by the city of New York and approximately 40 counties across New York State. Several of these cases have been transferred to the AWP multi-district litigation proceedings pending in the U.S. District Court for the District of Massachusetts for pretrial proceedings. Others of these cases will likely be litigated in the state courts in which they were filed. Each of the cases seeks an unspecified amount in money damages, civil penalties and/or treble damages, counsel fees and costs, and injunctive relief. In each of these matters, with the exception of the Florida, Idaho, South Carolina AG and Texas actions and the actions brought by various counties in New York, excluding the actions brought by Erie, Oswego and Schenectady counties, Mylan Labs, MPI and/or UDL have answered the respective complaints denying liability. Mylan Labs and its subsidiaries intend to defend each of these actions vigorously.

In addition, by letter dated January 12, 2005, MPI was notified by the U.S. Department of Justice of an investigation concerning MPI's calculations of Medicaid drug rebates. MPI is cooperating fully with the government's investigation.

Table of Contents

Modafinil Antitrust Litigation and FTC Inquiry

Beginning in April 2006, Mylan Labs, along with four other drug manufacturers, has been named in a series of civil lawsuits filed in the Eastern District of Pennsylvania by a variety of plaintiffs purportedly representing direct and indirect purchasers of the drug modafinil and one action brought by Apotex, Inc., a manufacturer of generic drugs seeking approval to market a generic modafinil product. These actions allege violations of federal and state laws in connection with the defendants' settlement of patent litigation relating to modafinil. These actions are in their preliminary stages, and motions to dismiss each action are pending. Mylan Labs intends to defend each of these actions vigorously. In addition, by letter dated July 11, 2006, Mylan was notified by the U.S. Federal Trade Commission (FTC) of an investigation relating to the settlement of the modafinil patent litigation. In its letter, the FTC requested certain information from Mylan Labs, MPI and Mylan Technologies Inc. pertaining to the patent litigation and the settlement thereof. On March 29, 2007, the FTC issued a subpoena, and on April 26, 2007, the FTC issued a civil investigative demand to Mylan Labs requesting additional information from the Company relating to the investigation. Mylan is cooperating fully with the government's investigation and its outstanding requests for information.

Other Litigation

The Company is involved in various other legal proceedings that are considered normal to its business. While it is not feasible to predict the ultimate outcome of such other proceedings, the Company believes that the ultimate outcome of such other proceedings will not have a material adverse effect on its financial position or results of operations.

ITEM 1A. Risk Factors

The following risk factors could have a material adverse effect on our business, financial position or results of operations and could cause the market value of our common stock to decline. These risk factors may not include all of the important factors that could affect our business or our industry or that could cause our future financial results to differ materially from historic or expected results or cause the market price of our common stock to fluctuate or decline.

OUR FUTURE REVENUE GROWTH AND PROFITABILITY ARE DEPENDENT UPON OUR ABILITY TO DEVELOP AND/OR LICENSE, OR OTHERWISE ACQUIRE, AND INTRODUCE NEW PRODUCTS ON A TIMELY BASIS IN RELATION TO OUR COMPETITORS' PRODUCT INTRODUCTIONS. OUR FAILURE TO DO SO SUCCESSFULLY COULD HAVE A MATERIAL ADVERSE EFFECT ON OUR FINANCIAL POSITION AND RESULTS OF OPERATIONS AND COULD CAUSE THE MARKET VALUE OF OUR COMMON STOCK TO DECLINE.

Our future revenues and profitability will depend, to a significant extent, upon our ability to successfully develop and/or license, or otherwise acquire and commercialize new generic and patent or statutorily protected (usually brand) pharmaceutical products in a timely manner. Product development is inherently risky, especially for new drugs for which safety and efficacy have not been established, and the market is not yet proven. Likewise, product licensing involves inherent risks including uncertainties due to matters that may affect the achievement of milestones, as well as the possibility of contractual disagreements with regard to terms such as license scope or termination rights. The development and commercialization process, particularly with regard to new drugs, also requires substantial time, effort and financial resources. We, or a partner, may not be successful in commercializing any of the products that we are developing or licensing (including, without limitation, nebivolol) on a timely basis, if at all, which could adversely affect our product introduction plans, financial position and results of operations and could cause the market value of our common stock to decline.

FDA approval is required before any prescription drug product, including generic drug products, can be marketed. The process of obtaining FDA approval to manufacture and market new and generic pharmaceutical products is rigorous, time consuming, costly and largely unpredictable. We, or a partner, may be unable to obtain requisite FDA approvals on a timely basis for new generic or brand products that we may develop, license or otherwise acquire. Also, for products pending approval, we may obtain raw materials or produce batches of

Table of Contents

inventory to be used in efficacy and bioequivalence testing, as well as in anticipation of the product's launch. In the event that FDA approval is denied or delayed, we could be exposed to the risk of this inventory becoming obsolete. The timing and cost of obtaining FDA approvals could adversely affect our product introduction plans, financial position and results of operations and could cause the market value of our common stock to decline.

The ANDA approval process often results in the FDA granting final approval to a number of ANDAs for a given product at the time a patent claim for a corresponding brand product or other market exclusivity expires. This often forces us to face immediate competition when we introduce a generic product into the market. Additionally, ANDA approvals often continue to be granted for a given product subsequent to the initial launch of the generic product. These circumstances generally result in significantly lower prices, as well as reduced margins, for generic products compared to brand products. New generic market entrants generally cause continued price and margin erosion over the generic product life cycle.

The Waxman-Hatch Act provides for a period of 180 days of generic marketing exclusivity for each ANDA applicant that is first to file an ANDA containing a certification of invalidity, non-infringement or unenforceability related to a patent listed with respect to a reference drug product, commonly referred to as a Paragraph IV certification. During this exclusivity period, which under certain circumstances may be required to be shared with other applicable ANDA sponsors with Paragraph IV certifications, the FDA cannot grant final approval to other ANDA sponsors holding applications for the same generic equivalent. If an ANDA containing a Paragraph IV certification is successful and the applicant is awarded exclusivity, it generally results in higher market share, net revenues and gross margin for that applicant. Even if we obtain FDA approval for our generic drug products, if we are not the first ANDA applicant to challenge a listed patent for such a product, we may lose significant advantages to a competitor that filed its ANDA containing such a challenge. The same would be true in situations where we are required to share our exclusivity period with other ANDA sponsors with Paragraph IV certifications. Such situations could have a material adverse effect on our ability to market that product profitably and on our financial position and results of operations, and the market value of our common stock could decline.

OUR ACQUISITION OF A CONTROLLING INTEREST IN MATRIX LABORATORIES AND OUR PLANS FOR FURTHER GLOBAL EXPANSION WITH THE ACQUISITION OF MERCK GENERICS EXPOSE THE COMPANY TO ADDITIONAL RISKS WHICH COULD HAVE A MATERIAL ADVERSE EFFECT ON OUR BUSINESS, FINANCIAL POSITION AND RESULTS OF OPERATIONS AND COULD CAUSE THE MARKET VALUE OF OUR COMMON STOCK TO DECLINE.

With our recently completed acquisition of Matrix and our planned acquisition of Merck Generics, Mylan's operations extend or will extend to numerous countries outside the U.S. Operating globally exposes us to certain additional risks including, but not limited to:

compliance with a variety of national and local laws of countries in which we do business, including restrictions on the import and export of certain intermediates, drugs and technologies, and the risk that our competitors may have more experience with operations in such countries or with international operations generally;

difficulties integrating new facilities in different countries into our existing operations, as well as integrating employees that we hire in different countries into our existing corporate culture;

failing to fully achieve identified financial and operating synergies;

fluctuations in exchange rates for transactions conducted in currencies other than the U.S. dollar;

adverse changes in the economies in which we operate as a result of a slowdown in overall growth, a change in government or economic liberalization policies, or financial instability in other countries who influence the economies in which we operate, particularly emerging markets;

wage increases or rising inflation in other countries in which we operate or will operate;

natural disasters, including drought, floods and earthquakes in other countries in which we operate or will operate; and

Table of Contents

communal disturbances, terrorist attacks, riots or regional hostilities in other countries in which we operate or will operate.

Certain of the above factors could have a material adverse effect on our business, financial position and results of operations and could cause a decline in the market value of our common stock.

OUR PLANNED ACQUISITION OF MERCK GENERICS SPECIFICALLY AND OUR ACQUISITION STRATEGY GENERALLY, INVOLVE A NUMBER OF INHERENT RISKS. THESE RISKS COULD CAUSE A MATERIAL ADVERSE EFFECT ON OUR BUSINESS, FINANCIAL POSITION AND RESULTS OF OPERATIONS AND COULD CAUSE THE MARKET VALUE OF OUR COMMON STOCK TO DECLINE.

We continually seek to expand our product line through complementary or strategic acquisitions of other companies, products and assets, and through joint ventures, licensing agreements or other arrangements. On May 12, 2007, we signed a definitive agreement to acquire Merck Generics. This transaction and any acquisitions, joint ventures and other business combinations involve various inherent risks, such as:

diversion of management's attention from our ongoing business;

the failure to assess accurately the values, strengths, weaknesses, contingent and other liabilities, regulatory compliance and potential profitability of acquisition or other transaction candidates;

the potential loss of key personnel or customers of an acquired business;

failing to successfully manage acquired businesses or increase our cash flow from their operations;

failing to successfully integrate the operations and personnel of the acquired businesses with our ongoing business, and our resulting inability to achieve identified financial and operating synergies anticipated to result from an acquisition or other transaction;

unanticipated changes in business and economic conditions affecting an acquisition or other transaction;

incurring substantial additional indebtedness, assuming liabilities and incurring significant additional capital expenditures, transaction and operating expenses and non-recurring acquisition-related charges;

potentially experiencing an adverse impact on our earnings from acquired in-process research and development and the write-off or amortization of acquired goodwill and other intangible assets;

acquiring businesses or entering new markets with which we are not familiar; and

international acquisitions, and other transactions, could also be affected by export controls, exchange rate fluctuations, domestic and foreign political conditions and the deterioration in domestic and foreign economic conditions.

We may be unable to realize synergies or other benefits expected to result from acquisitions, joint ventures and other transactions or investments we may undertake, or be unable to generate additional revenue to offset any unanticipated inability to realize these expected synergies or benefits. Realization of the anticipated benefits of acquisitions or other transactions could take longer than expected, and implementation difficulties, unforeseen expenses, complications and delays, market factors and the deterioration in domestic and global economic conditions could alter the anticipated

benefits of any such transactions. These factors could impair our growth and ability to compete, require us to focus resources on integration of operations rather than other profitable areas, otherwise cause a material adverse effect on our business, financial position and results of operations and could cause a decline in the market value of our common stock.

In addition, we may compete for certain acquisition targets with companies having greater financial resources than us or other advantages over us that may prevent us from acquiring a target.

We plan to finance the acquisition of Merck Generics through significant new indebtedness, cash on hand, cash provided by operating activities, and borrowings under our credit facilities, which will reduce our cash available for other purposes, including the repayment of indebtedness.

Table of Contents

WE ARE SUBJECT TO THE U.S. FOREIGN CORRUPT PRACTICES ACT AND SIMILAR WORLDWIDE ANTI-BRIBERY LAWS, WHICH IMPOSE RESTRICTIONS AND MAY CARRY SUBSTANTIAL PENALTIES. ANY VIOLATIONS OF THESE LAWS, OR ALLEGATIONS OF SUCH VIOLATIONS, COULD HAVE A MATERIAL ADVERSE EFFECT ON OUR BUSINESS, FINANCIAL POSITION AND RESULTS OF OPERATIONS AND COULD CAUSE THE MARKET VALUE OF OUR COMMON STOCK TO DECLINE.

The U.S. Foreign Corrupt Practices Act and similar anti-bribery laws in other jurisdictions generally prohibit companies and their intermediaries from making improper payments to non-U.S. officials for the purpose of obtaining or retaining business. Our policies mandate compliance with these anti-bribery laws, which often carry substantial penalties. We operate in jurisdictions that have experienced governmental corruption to some degree, and, in certain circumstances, strict compliance with anti-bribery laws may conflict with certain local customs and practices. We cannot assure you that our internal control policies and procedures always will protect us from reckless or other inappropriate acts committed by our affiliates, employees or agents. Violations of these laws, or allegations of such violations, could have a material adverse effect on our business, financial position and results of operations and could cause the market value of our common stock to decline.

WE HAVE GROWN, AND CONTINUE TO GROW, AT A VERY RAPID PACE. OUR INABILITY TO PROPERLY MANAGE OR SUPPORT THE GROWTH MAY HAVE A MATERIAL ADVERSE EFFECT ON OUR BUSINESS, FINANCIAL POSITION AND RESULTS OF OPERATIONS AND COULD CAUSE THE MARKET VALUE OF OUR COMMON STOCK TO DECLINE.

We have grown very rapidly over the past few years and anticipate continuing our rapid expansion including the planned acquisition of Merck Generics, extending our processes, systems and people. We expect to make significant investments in additional personnel, systems and internal control processes to help manage the growing company. Attracting, retaining and motivating key employees in various departments and locations to support our growth are critical to our business, and competition for these people can be intense. If we are unable to hire and retain qualified employees and if we do not continue to invest in systems and processes to manage and support our rapid growth, there may be a material adverse effect on our business, financial position and results of operations, and the market value of our common stock to decline.

OUR APPROVED PRODUCTS MAY NOT ACHIEVE EXPECTED LEVELS OF MARKET ACCEPTANCE, WHICH COULD HAVE A MATERIAL ADVERSE EFFECT ON OUR PROFITABILITY, FINANCIAL POSITION AND RESULTS OF OPERATIONS AND COULD CAUSE THE MARKET VALUE OF OUR COMMON STOCK TO DECLINE.

Even if we are able to obtain regulatory approvals for our new pharmaceutical products, generic or brand, the success of those products is dependent upon market acceptance. Levels of market acceptance for our new products could be impacted by several factors, including:

- the availability of alternative products from our competitors;
- the price of our products relative to that of our competitors;
- the timing of our market entry;
- the ability to market our products effectively to the retail level; and
- the acceptance of our products by government and private formularies.

Some of these factors are not within our control. Our new products may not achieve expected levels of market acceptance. Additionally, continuing studies of the proper utilization, safety and efficacy of pharmaceutical products are being conducted by the industry, government agencies and others. Such studies, which increasingly employ sophisticated methods and techniques, can call into question the utilization, safety and efficacy of previously marketed products. For example, on July 15, 2005, the FDA issued a Public Health Advisory regarding the safe use of transdermal fentanyl patches, a product we currently market, the loss of revenues of which could have a significant impact on our business. In some cases, studies have resulted, and may in the future result, in the

Table of Contents

discontinuance of product marketing or other risk management programs such as the need for a patient registry. These situations, should they occur, could have a material adverse effect on our profitability, financial position and results of operations, and the market value of our common stock could decline.

A RELATIVELY SMALL GROUP OF PRODUCTS MAY REPRESENT A SIGNIFICANT PORTION OF OUR NET REVENUES, GROSS PROFIT OR NET EARNINGS FROM TIME TO TIME. IF THE VOLUME OR PRICING OF ANY OF THESE PRODUCTS DECLINES, IT COULD HAVE A MATERIAL ADVERSE EFFECT ON OUR BUSINESS, FINANCIAL POSITION AND RESULTS OF OPERATIONS AND COULD CAUSE THE MARKET VALUE OF OUR COMMON STOCK TO DECLINE.

Sales of a limited number of our products often represent a significant portion of our net revenues, gross profit and net earnings. If the volume or pricing of our largest selling products declines in the future, our business, financial position and results of operations could be materially adversely affected, and the market value of our common stock could decline.

WE FACE VIGOROUS COMPETITION FROM OTHER PHARMACEUTICAL MANUFACTURERS THAT THREATENS THE COMMERCIAL ACCEPTANCE AND PRICING OF OUR PRODUCTS, WHICH COULD HAVE A MATERIAL ADVERSE EFFECT ON OUR BUSINESS, FINANCIAL POSITION AND RESULTS OF OPERATIONS AND COULD CAUSE THE MARKET VALUE OF OUR COMMON STOCK TO DECLINE.

Our competitors may be able to develop products and processes competitive with or superior to our own for many reasons, including that they may have:

proprietary processes or delivery systems;

larger research and development and marketing staffs;

larger production capabilities in a particular therapeutic area;

more experience in preclinical testing and human clinical trials;

more products; or

more experience in developing new drugs and financial resources, particularly with regard to brand manufacturers.

Any of these factors and others could have a material adverse effect on our business, financial position and results of operations and could cause the market value of our common stock to decline.

BECAUSE THE PHARMACEUTICAL INDUSTRY IS HEAVILY REGULATED, WE FACE SIGNIFICANT COSTS AND UNCERTAINTIES ASSOCIATED WITH OUR EFFORTS TO COMPLY WITH APPLICABLE REGULATIONS. SHOULD WE FAIL TO COMPLY WE COULD EXPERIENCE MATERIAL ADVERSE EFFECTS ON OUR BUSINESS, FINANCIAL POSITION AND RESULTS OF OPERATIONS, AND THE MARKET VALUE OF OUR COMMON STOCK COULD DECLINE.

The pharmaceutical industry is subject to regulation by various governmental authorities. For instance, we must comply with FDA requirements with respect to the manufacture, labeling, sale, distribution, marketing, advertising, promotion and development of pharmaceutical products. Failure to comply with FDA and other governmental regulations can result in fines, disgorgement, unanticipated compliance expenditures, recall or seizure of products,

total or partial suspension of production and/or distribution, suspension of the FDA's review of NDAs or ANDAs, enforcement actions, injunctions and criminal prosecution. Under certain circumstances, the FDA also has the authority to revoke previously granted drug approvals. Although we have internal regulatory compliance programs and policies and have had a favorable compliance history, there is no guarantee that these programs, as currently designed, will meet regulatory agency standards in the future. Additionally, despite our efforts at compliance, there is no guarantee that we may not be deemed to be deficient in some manner in the future. If we were deemed to be deficient in any significant way, our business, financial position and results of operations could be materially affected and the market value of our common stock could decline.

Table of Contents

In addition to the new drug approval process, the FDA also regulates the facilities and operational procedures that we use to manufacture our products. We must register our facilities with the FDA. All products manufactured in those facilities must be made in a manner consistent with current good manufacturing practices (cGMP). Compliance with cGMP regulations requires substantial expenditures of time, money and effort in such areas as production and quality control to ensure full technical compliance. The FDA periodically inspects our manufacturing facilities for compliance. FDA approval to manufacture a drug is site-specific. Failure to comply with cGMP regulations at one of our manufacturing facilities could result in an enforcement action brought by the FDA which could include withholding the approval of NDAs, ANDAs or other product applications of that facility. If the FDA were to require one of our manufacturing facilities to cease or limit production, our business could be adversely affected. Delay and cost in obtaining FDA approval to manufacture at a different facility also could have a material adverse effect on our business, financial position and results of operations and could cause the market value of our common stock to decline.

We are subject, as are generally all manufacturers, to various federal, state and local laws regulating working conditions, as well as environmental protection laws and regulations, including those governing the discharge of materials into the environment. Although we have not incurred significant costs associated with complying with environmental provisions in the past, if changes to such environmental laws and regulations are made in the future that require significant changes in our operations or if we engage in the development and manufacturing of new products requiring new or different environmental controls, we may be required to expend significant funds. Such changes could have a material adverse effect on our business, financial position and results of operations and could cause the market value of our common stock to decline.

OUR REPORTING AND PAYMENT OBLIGATIONS UNDER THE MEDICAID REBATE PROGRAM AND OTHER GOVERNMENTAL PURCHASING AND REBATE PROGRAMS ARE COMPLEX AND MAY INVOLVE SUBJECTIVE DECISIONS. ANY DETERMINATION OF FAILURE TO COMPLY WITH THOSE OBLIGATIONS COULD SUBJECT US TO PENALTIES AND SANCTIONS WHICH COULD HAVE A MATERIAL ADVERSE EFFECT ON OUR BUSINESS, FINANCIAL POSITION AND RESULTS OF OPERATIONS, AND THE MARKET VALUE OF OUR COMMON STOCK COULD DECLINE.

The regulations regarding reporting and payment obligations with respect to Medicaid reimbursement and rebates and other governmental programs are complex, and as discussed elsewhere in this Form 10-Q, we and other pharmaceutical companies are defendants in a number of suits filed by state attorneys general and have been notified of an investigation by the U.S. Department of Justice with respect to Medicaid reimbursement and rebates. Because our processes for these calculations and the judgments involved in making these calculations involve, and will continue to involve, subjective decisions and complex methodologies, these calculations are subject to the risk of errors. In addition, they are subject to review and challenge by the applicable governmental agencies, and it is possible that such reviews could result in material changes.

In addition, as also disclosed in this Form 10-Q, a number of state and federal government agencies are conducting investigations of manufacturers' reporting practices with respect to Average Wholesale Prices (AWP), in which they have suggested that reporting of inflated AWP has led to excessive payments for prescription drugs. We and numerous other pharmaceutical companies have been named as defendants in various actions relating to pharmaceutical pricing issues and whether allegedly improper actions by pharmaceutical manufacturers led to excessive payments by Medicare and/or Medicaid.

Any governmental agencies that have commenced, or may commence, an investigation of the Company could impose, based on a claim of violation of fraud and false claims laws or otherwise, civil and/or criminal sanctions, including fines, penalties and possible exclusion from federal health care programs (including Medicaid and Medicare). Some of the applicable laws may impose liability even in the absence of specific intent to defraud. Furthermore, should there

be ambiguity with regard to how to properly calculate and report payments-and even in the absence of any such ambiguity-a governmental authority may take a position contrary to a position we have taken, and may impose civil and/or criminal sanctions. Any such penalties or sanctions could have a material adverse effect on our business, financial position and results of operations and could cause the market value of our common stock to decline.

Table of Contents

WE EXPEND A SIGNIFICANT AMOUNT OF RESOURCES ON RESEARCH AND DEVELOPMENT EFFORTS THAT MAY NOT LEAD TO SUCCESSFUL PRODUCT INTRODUCTIONS. FAILURE TO SUCCESSFULLY INTRODUCE PRODUCTS INTO THE MARKET COULD HAVE A MATERIAL ADVERSE EFFECT ON OUR BUSINESS, FINANCIAL POSITION AND RESULTS OF OPERATIONS, AND THE MARKET VALUE OF OUR COMMON STOCK COULD DECLINE.

Much of our development effort is focused on technically difficult-to-formulate products and/or products that require advanced manufacturing technology. We conduct research and development primarily to enable us to manufacture and market FDA-approved pharmaceuticals in accordance with FDA regulations. Typically, research expenses related to the development of innovative compounds and the filing of NDAs are significantly greater than those expenses associated with ANDAs. As we continue to develop new products, our research expenses will likely increase. Because of the inherent risk associated with research and development efforts in our industry, particularly with respect to new drugs (including, without limitation, nebivolol), our, or a partner's, research and development expenditures may not result in the successful introduction of FDA approved new pharmaceutical products. Also, after we submit an NDA or ANDA, the FDA may request that we conduct additional studies and as a result, we may be unable to reasonably determine the total research and development costs to develop a particular product. Finally, we cannot be certain that any investment made in developing products will be recovered, even if we are successful in commercialization. To the extent that we expend significant resources on research and development efforts and are not able, ultimately, to introduce successful new products as a result of those efforts, our business, financial position and results of operations may be materially adversely affected, and the market value of our common stock could decline.

A SIGNIFICANT PORTION OF OUR NET REVENUES ARE DERIVED FROM SALES TO A LIMITED NUMBER OF CUSTOMERS. ANY SIGNIFICANT REDUCTION OF BUSINESS WITH ANY OF THESE CUSTOMERS COULD HAVE A MATERIAL ADVERSE EFFECT ON OUR BUSINESS, FINANCIAL POSITION AND RESULTS OF OPERATIONS, AND THE MARKET VALUE OF OUR COMMON STOCK COULD DECLINE.

A significant portion of our net revenues are derived from sales to a limited number of customers. As such, a reduction in or loss of business with one customer, or if one customer were to experience difficulty in paying us on a timely basis, our business, financial position and results of operations could be materially adversely affected, and the market value of our common stock could decline.

THE USE OF LEGAL, REGULATORY AND LEGISLATIVE STRATEGIES BY COMPETITORS, BOTH BRAND AND GENERIC, INCLUDING AUTHORIZED GENERICS AND CITIZEN S PETITIONS, AS WELL AS THE POTENTIAL IMPACT OF PROPOSED LEGISLATION, MAY INCREASE OUR COSTS ASSOCIATED WITH THE INTRODUCTION OR MARKETING OF OUR GENERIC PRODUCTS, COULD DELAY OR PREVENT SUCH INTRODUCTION AND/OR SIGNIFICANTLY REDUCE OUR PROFIT POTENTIAL. THESE FACTORS COULD HAVE A MATERIAL ADVERSE EFFECT ON OUR BUSINESS, FINANCIAL POSITION AND RESULTS OF OPERATIONS AND COULD CAUSE THE MARKET VALUE OF OUR COMMON STOCK TO DECLINE.

Our competitors, both brand and generic, often pursue strategies to prevent or delay competition from generic alternatives to brand products. These strategies include, but are not limited to:

entering into agreements whereby other generic companies will begin to market an authorized generic, a generic equivalent of a branded product, at the same time generic competition initially enters the market;

filing citizen's petitions with the FDA, including timing the filings so as to thwart generic competition by causing delays of our product approvals;

seeking to establish regulatory and legal obstacles that would make it more difficult to demonstrate bioequivalence;

initiating legislative efforts in various states to limit the substitution of generic versions of brand pharmaceuticals;

Table of Contents

filing suits for patent infringement that automatically delay FDA approval of many generic products;

introducing next-generation products prior to the expiration of market exclusivity for the reference product, which often materially reduces the demand for the first generic product for which we seek FDA approval;

obtaining extensions of market exclusivity by conducting clinical trials of brand drugs in pediatric populations or by other potential methods as discussed below;

persuading the FDA to withdraw the approval of brand name drugs for which the patents are about to expire, thus allowing the brand name company to obtain new patented products serving as substitutes for the products withdrawn; and

seeking to obtain new patents on drugs for which patent protection is about to expire.

The Food and Drug Modernization Act of 1997 includes a pediatric exclusivity provision that may provide an additional six months of market exclusivity for indications of new or currently marketed drugs if certain agreed upon pediatric studies are completed by the applicant. Brand companies are utilizing this provision to extend periods of market exclusivity.

Some companies have lobbied Congress for amendments to the Waxman-Hatch legislation that would give them additional advantages over generic competitors. For example, although the term of a company's drug patent can be extended to reflect a portion of the time an NDA is under regulatory review, some companies have proposed extending the patent term by a full year for each year spent in clinical trials rather than the one-half year that is currently permitted.

If proposals like these were to become effective, our entry into the market and our ability to generate revenues associated with new products may be delayed, reduced or eliminated, which could have a material adverse effect on our business, financial position and results of operations and could cause the market value of our common stock to decline.

THE INDENTURE FOR OUR SENIOR NOTES, OUR CREDIT FACILITIES AND ANY ADDITIONAL INDEBTEDNESS WE INCUR IN THE FUTURE IMPOSE, OR MAY IMPOSE, SIGNIFICANT OPERATING AND FINANCIAL RESTRICTIONS, WHICH MAY PREVENT US FROM CAPITALIZING ON BUSINESS OPPORTUNITIES AND TAKING SOME ACTIONS. THESE FACTORS COULD HAVE A MATERIAL ADVERSE EFFECT ON OUR BUSINESS, FINANCIAL POSITION AND RESULTS OF OPERATIONS AND COULD CAUSE THE MARKET VALUE OF OUR COMMON STOCK TO DECLINE.

The indenture for our Senior Notes, our credit facilities and any additional indebtedness we incur in the future impose, or may impose, significant operating and financial restrictions on us. These restrictions limit the ability of us and our subsidiaries to, among other things, incur additional indebtedness at our subsidiaries, make investments, sell assets, incur certain liens, and enter into agreements restricting our subsidiaries' ability to pay dividends, or merge or consolidate. In addition, our senior credit facility requires us to maintain specified financial ratios. We cannot assure you that these covenants will not adversely affect our ability to finance our future operations or capital needs or to pursue available business opportunities. A breach of any of these covenants or our inability to maintain the required financial ratios could result in a default under the related indebtedness. If a default occurs, the relevant lenders could elect to declare our indebtedness, together with accrued interest and other fees, to be immediately due and payable. These factors could have a material adverse effect on our business, financial position and results of operations and could cause the market value of our common stock to decline.

Table of Contents

OUR ABILITY TO SERVICE OUR DEBT AND MEET OUR CASH REQUIREMENTS DEPENDS ON MANY FACTORS, SOME OF WHICH ARE BEYOND OUR CONTROL. THESE FACTORS COULD HAVE A MATERIAL ADVERSE EFFECT ON OUR BUSINESS, FINANCIAL POSITION AND RESULTS OF OPERATIONS AND COULD CAUSE THE MARKET VALUE OF OUR COMMON STOCK TO DECLINE.

Our ability to satisfy our obligations, including our Senior Notes, our credit facilities and any additional indebtedness we incur in the future will depend on our future operating performance and financial results, which will be subject, in part, to factors beyond our control, including interest rates and general economic, financial and business conditions. If we are unable to generate sufficient cash flow, we may be required to: refinance all or a portion of our debt, including the notes and our senior credit facility; obtain additional financing in the future for acquisitions, working capital, capital expenditures and general corporate or other purposes; redirect a substantial portion of our cash flow to debt service, which as a result, might not be available for our operations or other purposes; sell some of our assets or operations; reduce or delay capital expenditures; or revise or delay our operations or strategic plans. If we are required to take any of these actions, it could have a material adverse effect on our business, financial condition or results of operations. In addition, we cannot assure you that we would be able to take any of these actions, that these actions would enable us to continue to satisfy our capital requirements or that these actions would be permitted under the terms of our credit facilities and the indenture governing the notes. The leverage resulting from our notes offering, our credit facility and indebtedness we may incur in the future could have certain material adverse effects on us, including limiting our ability to obtain additional financing and reducing cash available for our operations and acquisitions. As a result, our ability to withstand competitive pressures may be decreased and, we may be more vulnerable to economic downturns, which in turn could reduce our flexibility in responding to changing business, regulatory and economic conditions. These factors could have a material adverse effect on our business, financial position and results of operations and could cause the market value of our common stock to decline.

WE DEPEND ON THIRD-PARTY SUPPLIERS AND DISTRIBUTORS FOR THE RAW MATERIALS, PARTICULARLY THE CHEMICAL COMPOUND(S) COMPRISING THE ACTIVE PHARMACEUTICAL INGREDIENT, THAT WE USE TO MANUFACTURE OUR PRODUCTS, AS WELL AS CERTAIN FINISHED GOODS. A PROLONGED INTERRUPTION IN THE SUPPLY OF SUCH PRODUCTS COULD HAVE A MATERIAL ADVERSE EFFECT ON OUR BUSINESS, FINANCIAL POSITION AND RESULTS OF OPERATIONS, AND THE MARKET VALUE OF OUR COMMON STOCK COULD DECLINE.

We typically purchase the active pharmaceutical ingredient (i.e. the chemical compounds that produce the desired therapeutic effect in our products) and other materials and supplies that we use in our manufacturing operations, as well as certain finished products, from many different foreign and domestic suppliers.

Additionally, we maintain safety stocks in our raw materials inventory, and in certain cases where we have listed only one supplier in our applications with the FDA, have received FDA approval to use alternative suppliers should the need arise. However, there is no guarantee that we will always have timely and sufficient access to a critical raw material or finished product. A prolonged interruption in the supply of a single-sourced raw material, including the active ingredient, or finished product could cause our financial position and results of operations to be materially adversely affected, and the market value of our common stock could decline. In addition, our manufacturing capabilities could be impacted by quality deficiencies in the products which our suppliers provide, which could have a material adverse effect on our business, financial position and results of operations, and the market value of our common stock could decline.

The Company utilizes controlled substances in certain of its current products and products in development and therefore must meet the requirements of the Controlled Substances Act of 1970 and the related regulations administered by the Drug Enforcement Administration (DEA). These regulations relate to the manufacture, shipment, storage, sale and use of controlled substances. The DEA limits the availability of the active ingredients used in certain

of our current products and products in development and, as a result, our procurement quota of these active ingredients may not be sufficient to meet commercial demand or complete clinical trials. We must annually apply to the DEA for procurement quota in order to obtain these substances. Any delay or refusal by the DEA in

Table of Contents

establishing our procurement quota for controlled substances could delay or stop our clinical trials or product launches, or could cause trade inventory disruptions for those products that have already been launched, which could have a material adverse effect on our business, financial position and results of operations and could cause the market value of our common stock to decline.

WE USE SEVERAL MANUFACTURING FACILITIES TO MANUFACTURE OUR PRODUCTS. HOWEVER, A SIGNIFICANT NUMBER OF OUR PRODUCTS ARE PRODUCED AT ONE LOCATION. PRODUCTION AT THIS FACILITY COULD BE INTERRUPTED, WHICH COULD HAVE A MATERIAL ADVERSE EFFECT ON OUR BUSINESS, FINANCIAL POSITION AND RESULTS OF OPERATIONS AND COULD CAUSE THE MARKET VALUE OF OUR COMMON STOCK TO DECLINE.

Although we have other facilities, we produce a significant number of our products at our largest manufacturing facility. A significant disruption at that facility, even on a short-term basis, could impair our ability to produce and ship products to the market on a timely basis, which could have a material adverse effect on our business, financial position and results of operations and could cause the market value of our common stock to decline.

WE MAY EXPERIENCE DECLINES IN THE SALES VOLUME AND PRICES OF OUR PRODUCTS AS THE RESULT OF THE CONTINUING TREND TOWARD CONSOLIDATION OF CERTAIN CUSTOMER GROUPS, SUCH AS THE WHOLESALE DRUG DISTRIBUTION AND RETAIL PHARMACY INDUSTRIES, AS WELL AS THE EMERGENCE OF LARGE BUYING GROUPS. THE RESULT OF SUCH DEVELOPMENTS COULD HAVE A MATERIAL ADVERSE EFFECT ON OUR BUSINESS, FINANCIAL POSITION AND RESULTS OF OPERATIONS AND COULD CAUSE THE MARKET VALUE OF OUR COMMON STOCK TO DECLINE.

We make a significant amount of our sales to a relatively small number of drug wholesalers and retail drug chains. These customers represent an essential part of the distribution chain of generic pharmaceutical products. Drug wholesalers and retail drug chains have undergone, and are continuing to undergo, significant consolidation. This consolidation may result in these groups gaining additional purchasing leverage and consequently increasing the product pricing pressures facing our business. Additionally, the emergence of large buying groups representing independent retail pharmacies and the prevalence and influence of managed care organizations and similar institutions potentially enable those groups to attempt to extract price discounts on our products. The result of these developments may have a material adverse effect on our business, financial position and results of operations and could cause the market value of our common stock to decline.

WE MAY BE UNABLE TO PROTECT OUR INTELLECTUAL AND OTHER PROPRIETARY PROPERTY IN AN EFFECTIVE MANNER, WHICH COULD HAVE A MATERIAL ADVERSE EFFECT ON OUR BUSINESS, FINANCIAL POSITION AND RESULTS OF OPERATIONS AND COULD CAUSE THE MARKET VALUE OF OUR COMMON STOCK TO DECLINE.

Although our brand products may have patent protection, this may not prevent other companies from developing functionally equivalent products or from challenging the validity or enforceability of our patents. If any patents we use in our business are found or even alleged to be non-infringed, invalid or not enforceable, we could experience an adverse effect on our ability to commercially promote our patented products. We could be required to enforce our patent or other intellectual property rights through litigation, which can be protracted and involve significant expense and an inherently uncertain outcome. Any negative outcome could have a material adverse effect on our business, financial position and results of operations and could cause the market value of our common stock to decline.

Table of Contents

OUR COMPETITORS INCLUDING BRAND COMPANIES OR OTHER THIRD PARTIES MAY ALLEGE THAT WE ARE INFRINGING THEIR INTELLECTUAL PROPERTY, FORCING US TO EXPEND SUBSTANTIAL RESOURCES IN RESULTING LITIGATION, THE OUTCOME OF WHICH IS UNCERTAIN. ANY UNFAVORABLE OUTCOME OF SUCH LITIGATION COULD HAVE A MATERIAL ADVERSE EFFECT ON OUR BUSINESS, FINANCIAL POSITION AND RESULTS OF OPERATIONS AND COULD CAUSE THE MARKET VALUE OF OUR COMMON STOCK TO DECLINE.

Companies that produce brand pharmaceutical products routinely bring litigation against ANDA applicants that seek FDA approval to manufacture and market generic forms of their branded products. These companies allege patent infringement or other violations of intellectual property rights as the basis for filing suit against an ANDA applicant. Likewise, patent holders may bring patent infringement suits against companies that are currently marketing and selling their approved generic products. Litigation often involves significant expense and can delay or prevent introduction or sale of our generic products.

There may also be situations where the Company uses its business judgment and decides to market and sell products, notwithstanding the fact that allegations of patent infringement(s) have not been finally resolved by the courts. The risk involved in doing so can be substantial because the remedies available to the owner of a patent for infringement include, among other things, damages measured by the profits lost by the patent owner and not by the profits earned by the infringer. In the case of a willful infringement, the definition of which is subjective, such damages may be trebled. Moreover, because of the discount pricing typically involved with bioequivalent products, patented brand products generally realize a substantially higher profit margin than bioequivalent products. An adverse decision in a case such as this or in other similar litigation could have a material adverse effect on our business, financial position and results of operations and could cause the market value of our common stock to decline.

WE MAY EXPERIENCE REDUCTIONS IN THE LEVELS OF REIMBURSEMENT FOR PHARMACEUTICAL PRODUCTS BY GOVERNMENTAL AUTHORITIES, HMOs OR OTHER THIRD-PARTY PAYERS. ANY SUCH REDUCTIONS COULD HAVE A MATERIAL ADVERSE EFFECT ON OUR BUSINESS, FINANCIAL POSITION AND RESULTS OF OPERATIONS AND COULD CAUSE THE MARKET VALUE OF OUR COMMON STOCK TO DECLINE.

Various governmental authorities and private health insurers and other organizations, such as HMOs, provide reimbursement to consumers for the cost of certain pharmaceutical products. Demand for our products depends in part on the extent to which such reimbursement is available. Third-party payers increasingly challenge the pricing of pharmaceutical products. This trend and other trends toward the growth of HMOs, managed health care and legislative health care reform create significant uncertainties regarding the future levels of reimbursement for pharmaceutical products. Further, any reimbursement may be reduced in the future, perhaps to the point that market demand for our products declines. Such a decline could have a material adverse effect on our business, financial position and results of operations and could cause the market value of our common stock to decline.

LEGISLATIVE OR REGULATORY PROGRAMS THAT MAY INFLUENCE PRICES OF PRESCRIPTION DRUGS COULD HAVE A MATERIAL ADVERSE EFFECT ON OUR BUSINESS, FINANCIAL POSITION AND RESULTS OF OPERATIONS AND COULD CAUSE THE MARKET VALUE OF OUR COMMON STOCK TO DECLINE.

Current or future federal or state laws and regulations may influence the prices of drugs and, therefore, could adversely affect the prices that we receive for our products. Programs in existence in certain states seek to set prices of all drugs sold within those states through the regulation and administration of the sale of prescription drugs. Expansion of these programs, in particular, state Medicaid programs, or changes required in the way in which Medicaid rebates are calculated under such programs, could adversely affect the price we receive for our products and

could have a material adverse effect on our business, financial position and results of operations and could cause the market value of our common stock to decline.

Table of Contents

WE ARE INVOLVED IN VARIOUS LEGAL PROCEEDINGS AND CERTAIN GOVERNMENT INQUIRIES AND MAY EXPERIENCE UNFAVORABLE OUTCOMES OF SUCH PROCEEDINGS OR INQUIRIES, WHICH COULD HAVE A MATERIAL ADVERSE EFFECT ON OUR BUSINESS, FINANCIAL POSITION AND RESULTS OF OPERATIONS AND COULD CAUSE THE MARKET VALUE OF OUR COMMON STOCK TO DECLINE.

We are involved in various legal proceedings and certain government inquiries, including, but not limited to, patent infringement, product liability, breach of contract and claims involving Medicaid and Medicare reimbursements, some of which are described in our periodic reports and involve claims for, or the possibility of fines and penalties involving, substantial amounts of money or other relief. If any of these legal proceedings or inquiries were to result in an adverse outcome, the impact could have a material adverse effect on our business, financial position and results of operations and could cause the market value of our common stock to decline.

With respect to product liability, the Company maintains commercial insurance to protect against and manage a portion of the risks involved in conducting its business. Although we carry insurance, we believe that no reasonable amount of insurance can fully protect against all such risks because of the potential liability inherent in the business of producing pharmaceuticals for human consumption. To the extent that a loss occurs, depending on the nature of the loss and the level of insurance coverage maintained, it could have a material adverse effect on our business, financial position and results of operations and could cause the market value of our common stock to decline.

WE ENTER INTO VARIOUS AGREEMENTS IN THE NORMAL COURSE OF BUSINESS WHICH PERIODICALLY INCORPORATE PROVISIONS WHEREBY WE INDEMNIFY THE OTHER PARTY TO THE AGREEMENT. IN THE EVENT THAT WE WOULD HAVE TO PERFORM UNDER THESE INDEMNIFICATION PROVISIONS, IT COULD HAVE A MATERIAL ADVERSE EFFECT ON OUR BUSINESS, FINANCIAL POSITION AND RESULTS OF OPERATIONS AND COULD CAUSE THE MARKET VALUE OF OUR COMMON STOCK TO DECLINE.

In the normal course of business, we periodically enter into employment, legal settlement, and other agreements which incorporate indemnification provisions. We maintain insurance coverage which we believe will effectively mitigate our obligations under certain of these indemnification provisions. However, should our obligation under an indemnification provision exceed our coverage or should coverage be denied, our business, financial position and results of operations could be materially affected and the market value of our common stock could decline.

OUR FUTURE SUCCESS IS HIGHLY DEPENDENT ON OUR CONTINUED ABILITY TO ATTRACT AND RETAIN KEY PERSONNEL. ANY FAILURE TO ATTRACT AND RETAIN KEY PERSONNEL COULD HAVE A MATERIAL ADVERSE EFFECT ON OUR BUSINESS, FINANCIAL POSITION AND RESULTS OF OPERATIONS AND COULD CAUSE THE MARKET VALUE OF OUR COMMON STOCK TO DECLINE.

Because our success is largely dependent on the scientific nature of our business, it is imperative that we attract and retain qualified personnel in order to develop new products and compete effectively. If we fail to attract and retain key scientific, technical or management personnel, our business could be affected adversely. Additionally, while we have employment agreements with certain key employees in place, their employment for the duration of the agreement is not guaranteed. If we are unsuccessful in retaining all of our key employees, it could have a material adverse effect on our business, financial position and results of operations and could cause the market value of our common stock to decline.

Table of Contents

RECENT DECISIONS BY THE FDA, CURRENT BRAND TACTICS AND OTHER FACTORS BEYOND OUR CONTROL HAVE PLACED OUR BUSINESS UNDER INCREASING PRESSURE, WHICH COULD HAVE A MATERIAL ADVERSE EFFECT ON OUR BUSINESS, FINANCIAL POSITION AND RESULTS OF OPERATIONS AND COULD CAUSE THE MARKET VALUE OF OUR COMMON STOCK TO DECLINE.

We believe that certain recent FDA rulings are contrary to multiple sections of the Federal Food, Drug, and Cosmetic Act and the Administrative Procedures Act, the FDA's published regulations and the legal precedent on point. These decisions call into question the rules of engagement in our industry and have added a level of unpredictability that may materially adversely affect our business and the generic industry as a whole. While we continue to challenge these recent decisions as well as current brand tactics that undermine congressional intent, we cannot guarantee that we will prevail or predict when or if these matters will be rectified. If they are not, our business, financial position and results of operations could suffer and the market value of our common stock could decline.

WE HAVE BEGUN THE IMPLEMENTATION OF AN ENTERPRISE RESOURCE PLANNING SYSTEM. AS WITH ANY IMPLEMENTATION OF A SIGNIFICANT NEW SYSTEM, DIFFICULTIES ENCOUNTERED COULD RESULT IN BUSINESS INTERRUPTIONS, AND COULD HAVE A MATERIAL ADVERSE EFFECT ON OUR BUSINESS, FINANCIAL POSITION AND RESULTS OF OPERATIONS AND COULD CAUSE THE MARKET VALUE OF OUR COMMON STOCK TO DECLINE.

We have begun the implementation of an enterprise resource planning (ERP) system to enhance operating efficiencies and provide more effective management of our business operations. Implementations of ERP systems and related software carry risks such as cost overruns, project delays and business interruptions and delays. If we experience a material business interruption as a result of our ERP implementation, it could have a material adverse effect on our business, financial position and results of operations and could cause the market value of our common stock to decline.

CHANGING THE FISCAL YEAR END INVOLVES INCREMENTAL WORK AND COMPLEXITIES AND RESULTS IN THE ACCELERATION OF CERTAIN DEADLINES. FAILURE TO MEET THESE ACCELERATED DEADLINES AND/OR ISSUES RESULTING FROM THE ADDITIONAL WORK AND COMPLEXITIES COULD IMPACT OUR RESULTS OF OPERATIONS AND CAUSE OUR STOCK TO DECLINE.

The Company has announced its current plans to change its fiscal year end from March 31st to December 31st. While the Board of Directors has not yet acted to change the bylaws to effect this change, the planned approach, once implemented, would involve significant incremental work as well as certain complexities and expedited deadlines. Among them are the need to reconfigure certain internal processes and systems, the acceleration of effectiveness testing for certain Sarbanes-Oxley compliance measures for Mylan and its subsidiaries, and accelerated external audit timing and reporting, including the potential impact of the pending Merck Generics acquisition. Issues may arise as a result of these additional complexities or expedited deadlines or we may fail to meet compliance requirements within these accelerated deadlines which could adversely affect our financial position and results of operations and could cause the market value of our common stock to decline.

WE MUST MAINTAIN ADEQUATE INTERNAL CONTROLS AND BE ABLE, ON AN ANNUAL BASIS, TO PROVIDE AN ASSERTION AS TO THE EFFECTIVENESS OF SUCH CONTROLS. FAILURE TO MAINTAIN ADEQUATE INTERNAL CONTROLS OR TO IMPLEMENT NEW OR IMPROVED CONTROLS COULD HAVE A MATERIAL ADVERSE EFFECT ON OUR BUSINESS, FINANCIAL POSITION AND RESULTS OF OPERATIONS AND COULD CAUSE THE MARKET VALUE OF OUR COMMON STOCK TO DECLINE.

Effective internal controls are necessary for the Company to provide reasonable assurance with respect to its financial reports. We are spending a substantial amount of management time and resources to comply with changing laws, regulations and standards relating to corporate governance and public disclosure, including the Sarbanes-Oxley

Table of Contents

Act of 2002, new SEC regulations and the New York Stock Exchange rules. In particular, Section 404 of the Sarbanes-Oxley Act of 2002 requires management's annual review and evaluation of our internal control over financial reporting and attestations as to the effectiveness of these controls by our independent registered public accounting firm. If we fail to maintain the adequacy of our internal controls, we may not be able to ensure that we can conclude on an ongoing basis that we have effective internal control over financial reporting. Additionally, internal control over financial reporting may not prevent or detect misstatements because of its inherent limitations, including the possibility of human error, the circumvention or overriding of controls, or fraud. Therefore, even effective internal controls can provide only reasonable assurance with respect to the preparation and fair presentation of financial statements. In addition, projections of any evaluation of effectiveness of internal control over financial reporting to future periods are subject to the risk that the control may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate. If the Company fails to maintain the adequacy of its internal controls, including any failure to implement required new or improved controls, this could have a material adverse effect on our business, financial position and results of operations, and the market value of our common stock could decline.

During fiscal year 2007 the Company acquired a controlling stake in Matrix. For purposes of Management's evaluation of our internal control over financial reporting as of March 31, 2007 we elected to exclude Matrix from the scope of management's assessment as permitted by guidance provided by the Securities and Exchange Commission (SEC). This acquired business will be included in management's assessment of the effectiveness of the Company's internal controls over financial reporting in fiscal year 2008. If the Company fails to implement and maintain adequate internal controls at Matrix, it could have a material adverse effect on our business, financial position and results of operations, and the market value of our common stock could decline.

THERE ARE INHERENT UNCERTAINTIES INVOLVED IN ESTIMATES, JUDGMENTS AND ASSUMPTIONS USED IN THE PREPARATION OF FINANCIAL STATEMENTS IN ACCORDANCE WITH GAAP. ANY FUTURE CHANGES IN ESTIMATES, JUDGMENTS AND ASSUMPTIONS USED OR NECESSARY REVISIONS TO PRIOR ESTIMATES, JUDGMENTS OR ASSUMPTIONS OR CHANGES IN ACCOUNTING STANDARDS COULD LEAD TO A RESTATEMENT OR REVISION TO PREVIOUSLY CONSOLIDATED FINANCIAL STATEMENTS WHICH COULD HAVE A MATERIAL ADVERSE EFFECT ON OUR BUSINESS, FINANCIAL POSITION AND RESULTS OF OPERATIONS AND COULD CAUSE THE MARKET VALUE OF OUR COMMON STOCK TO DECLINE. IN ADDITION, WE ARE NOT PROVIDING ESTIMATED EPS GUIDANCE FOR FISCAL YEAR 2008 AND CAUTION THAT INVESTORS SHOULD NOT RELY ON ESTIMATES MADE BY OTHERS.

The consolidated and condensed consolidated financial statements included in the periodic reports we file with the SEC are prepared in accordance with accounting principles generally accepted in the United States of America (GAAP). The preparation of financial statements in accordance with GAAP involves making estimates, judgments and assumptions that affect reported amounts of assets (including intangible assets), liabilities, revenues, expenses (including acquired in process research and development) and income. Estimates, judgments and assumptions are inherently subject to change in the future and any necessary revisions to prior estimates, judgments or assumptions could lead to a restatement. Also, any new or revised accounting standards may require adjustments to previously issued financial statements. Any such changes could result in corresponding changes to the amounts of assets (including goodwill and other intangible assets), liabilities, revenues, expenses (including acquired in process research and development) and income. Any such changes could have a material adverse effect on our business, financial position and results of operations and could cause the market value of our common stock to decline.

On February 1, 2007, we announced that for fiscal 2008 we will not be providing detailed earnings guidance. Any third-party estimates of our expected earnings per share have been and will be made without our participation or endorsement. Because these estimates may be inaccurate, we caution against reliance upon them in making an

investment decision.

ITEM 5. *OTHER INFORMATION*

None.

Table of Contents

ITEM 6. EXHIBITS

- 3.1 Amended and Restated Articles of Incorporation of the registrant, as amended to date, filed as Exhibit 3.1 to the Form 10-Q for the quarterly period ended June 30, 2003, and incorporated herein by reference.
- 3.2 Bylaws of the registrant, as amended to date, filed as Exhibit 3.1 to the Report of Form 8-K filed on February 22, 2005, and incorporated herein by reference.
- 4.1(a) Rights Agreement dated as of August 22, 1996, between the registrant and American Stock Transfer & Trust Company, filed as Exhibit 4.1 to the Report on Form 8-K filed with the SEC on September 3, 1996, and incorporated herein by reference.
- 4.1(b) Amendment to Rights Agreement dated as of November 8, 1999, between the registrant and American Stock Transfer & Trust Company, filed as Exhibit 1 to Form 8-A/A filed with the SEC on March 31, 2000, and incorporated herein by reference.
- 4.1(c) Amendment No. 2 to Rights Agreement dated as of August 13, 2004, between the registrant and American Stock Transfer & Trust Company, filed as Exhibit 4.1 to the Report on Form 8-K filed with the SEC on August 16, 2004, and incorporated herein by reference.
- 4.1(d) Amendment No. 3 to Rights Agreement dated as of September 8, 2004, between the registrant and American Stock Transfer & Trust Company, filed as Exhibit 4.1 to the Report on Form 8-K filed with the SEC on September 9, 2004, and incorporated herein by reference.
- 4.1(e) Amendment No. 4 to Rights Agreement dated as of December 2, 2004, between the registrant and American Stock Transfer & Trust Company, filed as Exhibit 4.1 to the Report on Form 8-K filed with the SEC on December 3, 2004, and incorporated herein by reference.
- 4.1(f) Amendment No. 5 to Rights Agreement dated as of December 19, 2005, between the registrant and American Stock Transfer & Trust Company, filed as Exhibit 4.1 to the Report on Form 8-K filed with the SEC on December 19, 2005, and incorporated herein by reference.
- 4.2 Indenture, dated as of July 21, 2005, between the registrant and The Bank of New York, as trustee, filed as Exhibit 4.1 to the Report on Form 8-K filed with the SEC on July 27, 2005, and incorporated herein by reference.
- 4.3 Registration Rights Agreement, dated as of July 21, 2005, among the registrant, the Guarantors party thereto and Merrill Lynch, Pierce, Fenner & Smith Incorporated, BNY Capital Markets, Inc., KeyBanc Capital Markets (a Division of McDonald Investments Inc.), PNC Capital Markets, Inc. and SunTrust Capital Markets, Inc., filed as Exhibit 4.2 to the Report on Form 8-K filed with the SEC on July 27, 2005, and incorporated herein by reference.
- 10.1 Share Purchase Agreement dated May 12, 2007 by and among Merck Generics Holding GmbH, Merck Internationale Beteiligung GmbH, Merck KGaA and the registrant, filed with the Report on Form 8-K filed with the SEC on May 17, 2007, and incorporated herein by reference.
- 10.2 Commitment Letter dated May 11, 2007, from Merrill Lynch Capital Corporation, Citigroup Global Markets, Inc., and Goldman Sachs Credit Partners, to the registrant.
- 31.1 Certification of CEO pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
- 31.2 Certification of CFO pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
- 32 Certification of CEO and CFO pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

Table of Contents

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this Report on Form 10-Q for the quarterly period ended June 30, 2007, to be signed on its behalf by the undersigned thereunto duly authorized.

Mylan Laboratories Inc.
(Registrant)

By: /s/ Robert J. Coury

Robert J. Coury
Vice Chairman and Chief Executive Officer

August 7, 2007

/s/ Edward J. Borkowski
Edward J. Borkowski
Chief Financial Officer
(Principal financial officer)

August 7, 2007

/s/ Daniel C. Rizzo, Jr.
Daniel C. Rizzo, Jr.
Vice President and Corporate Controller
(Principal accounting officer)

August 7, 2007

Table of Contents

EXHIBIT INDEX

- 10.2 Commitment Letter dated May 11, 2007, from Merrill Lynch Capital Corporation, Citigroup Global Markets, Inc., and Goldman Sachs Credit Partners, to the registrant.
- 31.1 Certification of CEO pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
- 31.2 Certification of CFO pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
- 32 Certification of CEO and CFO pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.